D. de Zeeuw

D. de Zeeuw, R. Gansevoort, P. D. de Jong, 1995, Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association.

Renal Function as a Predictor of Outcome in a Broad Spectrum of Patients With Heart Failure

Hans L. Hillege, Karl Swedberg, Christopher B. Granger, 2006, Circulation.

Sodium‐glucose co‐transporter‐2 inhibitors with and without metformin: A meta‐analysis of cardiovascular, kidney and mortality outcomes

K. Mahaffey, G. Figtree, M. Jardine, 2020, Diabetes, obesity & metabolism.

Medication beliefs, treatment complexity, and non-adherence to different drug classes in patients with type 2 diabetes.

F. Haaijer-Ruskamp, D. de Zeeuw, P. Denig, 2014, Journal of psychosomatic research.

Lower estimated glomerular filtration rate and higher albuminuria are associated with mortality and end-stage renal disease. A collaborative meta-analysis of kidney disease population cohorts.

Laura E. Clark, M. Landray, F. Kronenberg, 2011, Kidney international.

Screening for albuminuria with subsequent screening for hypertension and hypercholesterolaemia identifies subjects in whom treatment is warranted to prevent cardiovascular events.

D. de Zeeuw, S. Bakker, R. Gansevoort, 2013, Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association.

The Role of Patients’ Age on Their Preferences for Choosing Additional Blood Pressure-Lowering Drugs: A Discrete Choice Experiment in Patients with Diabetes

F. Haaijer-Ruskamp, D. de Zeeuw, T. Dekker, 2015, PloS one.

ACE gene polymorphism and losartan treatment in type 2 diabetic patients with nephropathy.

J. Lunceford, B. Brenner, H. Parving, 2008, Journal of the American Society of Nephrology : JASN.

Antihypertensive Effect of a 5‐Day Infusion of Atrial Natriuretic Factor in Humans

D. de Zeeuw, P. D. de Jong, W. Janssen, 1989, Hypertension.

Longitudinal Estimated GFR Trajectories in Patients With and Without Type 2 Diabetes and Nephropathy.

H. Parving, G. Remuzzi, T. Greene, 2018, American journal of kidney diseases : the official journal of the National Kidney Foundation.

Canagliflozin, serum magnesium and cardiovascular outcomes—Analysis from the CANVAS Program

K. Mahaffey, M. Jardine, V. Perkovic, 2021, Endocrinology, diabetes & metabolism.

Low Molecular Weight Proteins as Carriers for Renal Drug Targeting: Naproxen–Lysozyme

D. de Zeeuw, D. Meijer, F. Moolenaar, 1991, Pharmaceutical Research.

Low Molecular Weight Proteins as Carriers for Renal Drug Targeting: Naproxen Coupled to Lysozyme via the Spacer L-Lactic Acid

D. de Zeeuw, D. Meijer, F. Moolenaar, 1993, Pharmaceutical Research.

A report with consensus statements of the International Society of Nephrology 2004 Consensus Workshop on Prevention of Progression of Renal Disease, Hong Kong, June 29, 2004.

R. Atkins, G. Remuzzi, B. Freedman, 2005, Kidney international. Supplement.

Trends in the incidence of treated end-stage renal failure in The Netherlands: hope for the future?

D. de Zeeuw, R. Gansevoort, P. D. de Jong, 2004, Kidney international. Supplement.

Review: Intracellular angiotensin II: from myth to reality?

R. Henning, D. de Zeeuw, C. Filipeanu, 2001, Journal of the renin-angiotensin-aldosterone system : JRAAS.

Renal tubular sensitivity to atrial natriuretic factor in essential hypertension

D. de Zeeuw, P. D. de Jong, W. Janssen, 1994, Journal of hypertension.

Reduction of proteinuria by angiotensin converting enzyme inhibition.

D. de Zeeuw, P. D. de Jong, D. Zeeuw, 1987, Kidney international.

Renin inhibition improves pressure natriuresis in essential hypertension.

G. Navis, P. van Paassen, D. de Zeeuw, 2000, Journal of the American Society of Nephrology : JASN.

Serum Bicarbonate and Kidney Disease Progression and Cardiovascular Outcome in Patients With Diabetic Nephropathy: A Post Hoc Analysis of the RENAAL (Reduction of End Points in Non-Insulin-Dependent Diabetes With the Angiotensin II Antagonist Losartan) Study and IDNT (Irbesartan Diabetic Nephropathy

J. Lewis, B. Wolffenbuttel, D. de Zeeuw, 2015, American journal of kidney diseases : the official journal of the National Kidney Foundation.

Angiotensin II does not acutely reverse the reduction of proteinuria by long-term ACE inhibition.

D. de Zeeuw, P. D. de Jong, G. K. van der Hem, 1991, Kidney international.

Estimated GFR decline as a surrogate end point for kidney failure: a post hoc analysis from the Reduction of End Points in Non-Insulin-Dependent Diabetes With the Angiotensin II Antagonist Losartan (RENAAL) study and Irbesartan Diabetic Nephropathy Trial (IDNT).

H. Parving, J. Coresh, A. Levey, 2014, American journal of kidney diseases : the official journal of the National Kidney Foundation.

The rate of progression of renal disease may not be slower in women compared with men: a patient-level meta-analysis.

C. Schmid, A. Levey, G. Remuzzi, 2003, Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association.

The reliability of different formulae to predict creatinine clearance

D. de Zeeuw, P. D. de Jong, J. Verhave, 2003, Journal of internal medicine.

International consensus definitions of clinical trial outcomes for kidney failure: 2020.

A. Levin, K. Mahaffey, V. Jha, 2020, Kidney international.

Comparison of exposure response relationship of atrasentan between North American and Asian populations

H. Parving, G. Remuzzi, V. Perkovic, 2017, Diabetes, obesity & metabolism.

Time course of the antiproteinuric and renal haemodynamic responses to losartan in microalbuminuric IDDM.

D. de Zeeuw, P. D. de Jong, R. Dullaart, 2001, Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association.

Canagliflozin and Renal Outcomes in Type 2 Diabetes and Nephropathy.

B. Zinman, C. Cannon, B. Brenner, 2019, The New England journal of medicine.

Albuminuria is a target for renoprotective therapy independent from blood pressure in patients with type 2 diabetic nephropathy: post hoc analysis from the Reduction of Endpoints in NIDDM with the Angiotensin II Antagonist Losartan (RENAAL) trial.

B. Brenner, H. Parving, G. Remuzzi, 2007, Journal of the American Society of Nephrology : JASN.

Moderate sodium restriction in hypertensive subjects: renal effects of ACE-inhibition.

A. Donker, D. de Zeeuw, P. D. de Jong, 1987, Kidney international.

Canagliflozin Reduces Kidney-Related Adverse Events in Type 2 Diabetes and CKD: Findings From the Randomized CREDENCE Trial.

A. Levin, M. Jardine, V. Perkovic, 2021, American journal of kidney diseases : the official journal of the National Kidney Foundation.

Effects of canagliflozin compared with placebo on major adverse cardiovascular and kidney events in patient groups with different baseline levels of HbA1c, disease duration and treatment intensity: results from the CANVAS Program

K. Mahaffey, M. Jardine, V. Perkovic, 2021, Diabetologia.

Effects of canagliflozin on serum potassium in the CANagliflozin cardioVascular Assessment Study (CANVAS) Program

V. Perkovic, D. de Zeeuw, M. Weir, 2020, Clinical kidney journal.

Effects of Canagliflozin on Cardiovascular, Renal, and Safety Outcomes in Participants With Type 2 Diabetes and Chronic Kidney Disease According to History of Heart Failure: Results From the CREDENCE Trial.

B. Zinman, C. Cannon, A. Levin, 2020, American heart journal.

Renal, Cardiovascular, and Safety Outcomes of Canagliflozin by Baseline Kidney Function: A Secondary Analysis of the CREDENCE Randomized Trial.

B. Zinman, C. Cannon, A. Levin, 2020, Journal of the American Society of Nephrology : JASN.

Different eGFR Decline Thresholds and Renal Effects of Canagliflozin: Data from the CANVAS Program.

K. Mahaffey, V. Perkovic, D. Matthews, 2020, Journal of the American Society of Nephrology : JASN.

Mediators of the Effects of Canagliflozin on Heart Failure in Patients With Type 2 Diabetes.

M. Woodward, K. Mahaffey, G. Figtree, 2020, JACC. Heart failure.

Canagliflozin and Cardiovascular and Renal Outcomes in Type 2 Diabetes Mellitus and Chronic Kidney Disease in Primary and Secondary Cardiovascular Prevention Groups

B. Zinman, C. Cannon, B. Brenner, 2019, Circulation.

Canagliflozin and Stroke in Type 2 Diabetes Mellitus

K. Mahaffey, V. Perkovic, D. Matthews, 2018, Stroke.

Effects of canagliflozin on amputation risk in type 2 diabetes: the CANVAS Program

K. Mahaffey, V. Perkovic, D. Matthews, 2019, Diabetologia.

Effects of Canagliflozin on Heart Failure Outcomes Associated With Preserved and Reduced Ejection Fraction in Type 2 Diabetes Mellitus.

K. Mahaffey, G. Figtree, V. Perkovic, 2019, Circulation.

Canagliflozin and fracture risk in individuals with type 2 diabetes: results from the CANVAS Program

K. Mahaffey, N. Watts, M. Jardine, 2019, Diabetologia.

Effects of Dapagliflozin on Circulating Markers of Phosphate Homeostasis.

G. Laverman, D. de Zeeuw, H. Heerspink, 2018, Clinical journal of the American Society of Nephrology : CJASN.

Impact of weight change on albuminuria in the general population.

A. Bello, D. de Zeeuw, S. Bakker, 2007, Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association.

The albuminuria‐lowering response to dapagliflozin is variable and reproducible among individual patients

G. Laverman, D. de Zeeuw, H. Heerspink, 2017, Diabetes, obesity & metabolism.

Direct interaction between the sympathetic and renin-angiotensin system in myocardial tissue: a microdialysis study in anaesthetised rats.

D. de Zeeuw, D. V. van Veldhuisen, W. V. van Gilst, 2000, Journal of the autonomic nervous system.

Change in Albuminuria and GFR as End Points for Clinical Trials in Early Stages of CKD: A Scientific Workshop Sponsored by the National Kidney Foundation in Collaboration With the US Food and Drug Administration and European Medicines Agency.

J. Coresh, H. Tighiouart, A. Levin, 2019, American journal of kidney diseases : the official journal of the National Kidney Foundation.

The angiotensin II receptor antagonist telmisartan reduces urinary albumin excretion in patients with isolated systolic hypertension: results of a randomized, double-blind, placebo-controlled trial

G. Navis, D. de Zeeuw, J. Reid, 2005, Journal of hypertension.

Enhanced responses of blood pressure, renal function, and aldosterone to angiotensin I in the DD genotype are blunted by low sodium intake.

R. Henning, G. Navis, D. de Zeeuw, 2002, Journal of the American Society of Nephrology : JASN.

Angiotensin-converting enzyme gene I/D polymorphism and renal disease

G. Navis, D. de Zeeuw, P. D. de Jong, 1999, Journal of Molecular Medicine.

Chronic beta-blocker treatment in patients with advanced heart failure. Effects on neurohormones.

D. de Zeeuw, D. V. van Veldhuisen, F. Boomsma, 2000, International journal of cardiology.

Uptake of angiotensin II receptor blockers in the treatment of hypertension

M. Sturkenboom, J. Greving, F. Haaijer-Ruskamp, 2005, European Journal of Clinical Pharmacology.

Dietary sodium restriction specifically potentiates left ventricular ACE inhibition by zofenopril, and is associated with attenuated hypertrophic response in rats with myocardial infarction

D. de Zeeuw, D. V. van Veldhuisen, H. Buikema, 2004, Journal of the renin-angiotensin-aldosterone system : JRAAS.

The Selective Vitamin D Receptor Activator for Albuminuria Lowering (VITAL) Study: Study Design and Baseline Characteristics

H. Parving, G. Remuzzi, D. de Zeeuw, 2009, American Journal of Nephrology.

High protein intake associates with cardiovascular events but not with loss of renal function.

D. de Zeeuw, S. Bakker, R. Gansevoort, 2009, Journal of the American Society of Nephrology : JASN.

High Dietary Sodium Blunts Effects of Angiotensin-converting Enzyme Inhibition on Vascular Angiotensin I–to–Angiotensin II Conversion in Rats

G. Navis, D. de Zeeuw, F. Boomsma, 2003, Journal of cardiovascular pharmacology.

Role of genetic variability in the renin-angiotensin system in diabetic and nondiabetic renal disease.

D. de Zeeuw, P. D. de Jong, A. Boonstra, 2001, Seminars in nephrology.

Myocardial infarction does not further impair renal damage in 5/6 nephrectomized rats.

R. Henning, D. de Zeeuw, R. P. van Dokkum, 2008, Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association.

Effect of first myocardial ischemic event on renal function.

D. de Zeeuw, H. Hillege, R. Gansevoort, 2007, The American journal of cardiology.

Accelerated decline and prognostic impact of renal function after myocardial infarction and the benefits of ACE inhibition: the CATS randomized trial.

D. Grobbee, D. Zeeuw, G. Navis, 2003, European heart journal.

Clinical trial in nephrology at hard end point?

D. de Zeeuw, P. D. de Graeff, 2004, Journal of the American Society of Nephrology : JASN.

Plasma 1,25-Dihydroxyvitamin D and the Risk of Developing Hypertension: The Prevention of Renal and Vascular End-Stage Disease Study.

M. M. Joosten, M. Visser, D. de Zeeuw, 2015, Hypertension.

Urinary proteomics predict onset of microalbuminuria in normoalbuminuric type 2 diabetic patients, a sub-study of the DIRECT-Protect 2 study

H. Parving, R. Klein, N. Chaturvedi, 2016, Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association.

Risk factors for long-term renal survival after renal transplantation: a role for angiotensin-converting enzyme (insertion/deletion) polymorphism?

D. Zeeuw, G. Navis, D. de Zeeuw, 1998, Journal of the American Society of Nephrology : JASN.

Insights from CREDENCE trial indicate an acute drop in estimated glomerular filtration rate during treatment with canagliflozin with implications for clinical practice.

B. Zinman, C. Cannon, A. Levin, 2020, Kidney international.

Drug-Induced Reduction in Albuminuria Is Associated with Subsequent Renoprotection: A Meta-Analysis.

J. Hoekman, D. de Zeeuw, H. Heerspink, 2015, Journal of the American Society of Nephrology : JASN.

Renal end points in clinical trials of kidney disease

D. de Zeeuw, H. Heerspink, M. Weldegiorgis, 2015, Current opinion in nephrology and hypertension.

Impact of the preintervention rate of renal function decline on outcome of renoprotective intervention.

G. Navis, D. de Zeeuw, P. D. de Jong, 2008, Clinical journal of the American Society of Nephrology : CJASN.

Precision of glomerular filtration rate determinations for long-term slope calculations is improved by simultaneous infusion of 125I-iothalamate and 131I-hippuran.

A. Donker, D. de Zeeuw, P. D. de Jong, 1996, Journal of the American Society of Nephrology : JASN.

Proteinuria: a risk factor for pregnancy-related renal function decline in primary glomerular disease?

D. de Zeeuw, V. Fidler, P. D. de Jong, 1995, American Journal of Kidney Diseases.

Long-term benefits of the antiproteinuric effect of angiotensin-converting enzyme inhibition in nondiabetic renal disease.

D. de Zeeuw, R. Gansevoort, P. D. de Jong, 1993, American journal of kidney diseases : the official journal of the National Kidney Foundation.

Have rational therapeutic principles emerged in treating hypertension in chronic renal failure?

D. de Zeeuw, R. Gansevoort, P. D. de Jong, 1993, American journal of kidney diseases : the official journal of the National Kidney Foundation.

Apparent loss of urinary albumin during long-term frozen storage: HPLC vs immunonephelometry.

D. de Zeeuw, S. Bakker, R. Gansevoort, 2007, Clinical chemistry.

Which method for quantifying urinary albumin excretion gives what outcome? A comparison of immunonephelometry with HPLC.

R. Gans, D. de Zeeuw, H. Hillege, 2004, Kidney international. Supplement.

Extended prognostic value of urinary albumin excretion for cardiovascular events.

D. de Zeeuw, S. Bakker, R. Gansevoort, 2008, Journal of the American Society of Nephrology.

Microalbuminuria as an early marker for cardiovascular disease.

H. Parving, R. Henning, D. de Zeeuw, 2006, Journal of the American Society of Nephrology : JASN.

An elevated urinary albumin excretion predicts de novo development of renal function impairment in the general population.

D. de Zeeuw, H. Hillege, S. Bakker, 2004, Kidney international. Supplement.

How to measure the prevalence of microalbuminuria in relation to age and gender?

D. de Zeeuw, H. Hillege, P. D. de Jong, 2002, American journal of kidney diseases : the official journal of the National Kidney Foundation.

Urinary albumin excretion and its relation with C-reactive protein and the metabolic syndrome in the prediction of type 2 diabetes.

D. de Zeeuw, H. Hillege, S. Bakker, 2005, Diabetes care.

The validity of screening based on spot morning urine samples to detect subjects with microalbuminuria in the general population.

J. Burgerhof, D. de Zeeuw, H. Hillege, 2005, Kidney international. Supplement.

Comparison of zofenopril and lisinopril to study the role of the sulfhydryl‐group in improvement of endothelial dysfunction with ACE‐inhibitors in experimental heart failure

H. Crijns, D. de Zeeuw, H. Buikema, 2000, British journal of pharmacology.

Trends in hyperlipidemia and hypertension management in type 2 diabetes patients from 1998–2004: a longitudinal observational study

J. Greving, F. Haaijer-Ruskamp, D. de Zeeuw, 2007, Cardiovascular diabetology.

Review: Relation Between Quality-of-Care Indicators for Diabetes and Patient Outcomes: A Systematic Literature Review

Petra Denig, F. Haaijer-Ruskamp, D. de Zeeuw, 2011, Medical care research and review : MCRR.

The kidney, a cardiovascular risk marker, and a new target for therapy.

D. de Zeeuw, H. Hillege, P. D. de Jong, 2005, Kidney international. Supplement.

Pathophysiology of Proteinuria: Albuminuria as a Target for Treatment

T. Rabelink, D. de Zeeuw, H. Heerspink, 2020 .

ESRD After Heart Failure, Myocardial Infarction, or Stroke in Type 2 Diabetic Patients With CKD.

S. Solomon, M. Pfeffer, J. McMurray, 2017, American journal of kidney diseases : the official journal of the National Kidney Foundation.

Renal outcomes with aliskiren in patients with type 2 diabetes: a prespecified secondary analysis of the ALTITUDE randomised controlled trial.

Akshay S. Desai, S. Solomon, M. Pfeffer, 2016, The lancet. Diabetes & endocrinology.

Is Doubling of Serum Creatinine a Valid Clinical ‘Hard’ Endpoint in Clinical Nephrology Trials?

V. Perkovic, D. de Zeeuw, H. L. Lambers Heerspink, 2011, Nephron Clinical Practice.

Prevention of chronic kidney and vascular disease: toward global health equity--the Bellagio 2004 Declaration.

R. Atkins, S. Agarwal, G. Remuzzi, 2005, Kidney international. Supplement.

Early renin‐angiotensin system intervention is more beneficial than late intervention in delaying end‐stage renal disease in patients with type 2 diabetes

H. Parving, G. Remuzzi, D. de Zeeuw, 2016, Diabetes, obesity & metabolism.

Relative incidence of ESRD versus cardiovascular mortality in proteinuric type 2 diabetes and nephropathy: results from the DIAMETRIC (Diabetes Mellitus Treatment for Renal Insufficiency Consortium) database.

R. Atkins, J. Lewis, D. de Zeeuw, 2012, American journal of kidney diseases : the official journal of the National Kidney Foundation.

Myocardial infarction enhances progressive renal damage in an experimental model for cardio-renal interaction.

R. Henning, D. de Zeeuw, H. van Goor, 2004, Journal of the American Society of Nephrology : JASN.

Creatinine Excretion Rate and Mortality in Type 2 Diabetes and Nephropathy

G. Navis, A. Kwakernaak, D. de Zeeuw, 2013, Diabetes Care.

First morning voids are more reliable than spot urine samples to assess microalbuminuria.

D. de Zeeuw, S. Bakker, R. Gansevoort, 2009, Journal of the American Society of Nephrology : JASN.

Kidney, Cardiovascular, and Safety Outcomes of Canagliflozin according to Baseline Albuminuria: A CREDENCE Secondary Analysis.

B. Zinman, C. Cannon, A. Levin, 2021, Clinical journal of the American Society of Nephrology : CJASN.

Screening for albuminuria identifies individuals at increased renal risk.

D. de Zeeuw, S. Bakker, R. Gansevoort, 2009, Journal of the American Society of Nephrology : JASN.

Renal damage after myocardial infarction is prevented by renin-angiotensin-aldosterone-system intervention.

R. Henning, D. de Zeeuw, H. Hillege, 2006, Journal of the American Society of Nephrology : JASN.

Altered myogenic constriction and endothelium-derived hyperpolarizing factor-mediated relaxation in small mesenteric arteries of hypertensive subtotally nephrectomized rats

R. Henning, D. de Zeeuw, S. Vettoretti, 2006, Journal of hypertension.

Determining the Optimal Protocol for Measuring an Albuminuria Class Transition in Clinical Trials in Diabetic Kidney Disease.

H. Parving, G. Remuzzi, R. Bilous, 2016, Journal of the American Society of Nephrology.

Angiotensin II antagonism improves the lipoprotein profile in patients with nephrotic syndrome

D. de Zeeuw, R. Gansevoort, P. D. de Jong, 1995, Journal of hypertension. Supplement : official journal of the International Society of Hypertension.

Renoprotection with and without blood pressure reduction.

H. Parving, G. Navis, G. Laverman, 2005, Kidney international. Supplement.

Renoprotective effects of VPI versus ACEI in normotensive nephrotic rats on different sodium intakes.

R. Henning, G. Navis, G. Laverman, 2003, Kidney international.

Renoprotection: a matter of blood pressure reduction or agent-characteristics?

G. Navis, D. de Zeeuw, L. Vogt, 2002, Journal of the American Society of Nephrology : JASN.

Optimal antiproteinuric dose of losartan in nondiabetic patients with nephrotic range proteinuria.

R. Henning, G. Navis, G. Laverman, 2001, American journal of kidney diseases : the official journal of the National Kidney Foundation.

Glomerular preload and afterload reduction as a tool to lower urinary protein leakage: will such treatments also help to improve renal function outcome?

D. de Zeeuw, P. D. de Jong, S. Anderson, 1993, Journal of the American Society of Nephrology : JASN.

Macroalbuminuria is a better risk marker than low estimated GFR to identify individuals at risk for accelerated GFR loss in population screening.

J. Wetzels, D. de Zeeuw, S. Bakker, 2006, Journal of the American Society of Nephrology : JASN.

Drawbacks of the use of indirect estimates of renal function to evaluate the effect of risk factors on renal function.

G. Curhan, D. de Zeeuw, H. Hillege, 2004, Journal of the American Society of Nephrology : JASN.

Impaired renal function in patients with ischemic and nonischemic chronic heart failure: association with neurohormonal activation and survival.

G. Navis, D. de Zeeuw, H. Hillege, 2004, American heart journal.

Diminished antiproteinuric effect of the angiotensin receptor blocker losartan during high potassium intake in patients with CKD

G. Navis, D. de Zeeuw, L. Vogt, 2021, Clinical kidney journal.

Effects of Canagliflozin in Patients with Baseline eGFR <30 ml/min per 1.73 m2: Subgroup Analysis of the Randomized CREDENCE Trial.

B. Zinman, C. Cannon, A. Levin, 2020, Clinical journal of the American Society of Nephrology : CJASN.

The future of Diabetic Kidney Disease management: reducing the unmet need

D. de Zeeuw, 2020, Journal of Nephrology.

Treating diabetic complications; from large randomized clinical trials to precision medicine

D. de Zeeuw, H. Heerspink, Hiddo J. L. Heerspink, 2018, Diabetes, obesity & metabolism.

Is a reduction in albuminuria associated with renal and cardiovascular protection? A post hoc analysis of the ALTITUDE trial

Akshay S. Desai, S. Solomon, M. Pfeffer, 2016, Diabetes, obesity & metabolism.

Unmet need in diabetic nephropathy: failed drugs or trials?

D. de Zeeuw, H. Heerspink, 2016, The lancet. Diabetes & endocrinology.

Renal effects of atorvastatin and rosuvastatin in patients with diabetes who have progressive renal disease (PLANET I): a randomised clinical trial.

H. Parving, G. Remuzzi, B. Molitoris, 2015, The lancet. Diabetes & endocrinology.

A prediction of the renal and cardiovascular efficacy of aliskiren in ALTITUDE using short-term changes in multiple risk markers

H. Parving, J. Hoekman, D. de Zeeuw, 2014, European journal of preventive cardiology.

Rationale and Trial Design of Bardoxolone Methyl Evaluation in Patients with Chronic Kidney Disease and Type 2 Diabetes: The Occurrence of Renal Events (BEACON)

J. McMurray, H. Parving, G. Remuzzi, 2013, American Journal of Nephrology.

Dual RAS Therapy Not on Target, but Fully Alive

D. de Zeeuw, H. L. Lambers Heerspink, 2010, Nephron Clinical Practice.

Effects of dietary sodium and hydrochlorothiazide on the antiproteinuric efficacy of losartan.

G. Navis, D. de Zeeuw, F. Boomsma, 2008, Journal of the American Society of Nephrology : JASN.

Potential role of active vitamin D in retarding the progression of chronic kidney disease.

D. de Zeeuw, Youhua Liu, L. Williams, 2006, Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association.

Albuminuria: a target for treatment of type 2 diabetic nephropathy.

D. de Zeeuw, 2007, Seminars in nephrology.

Update on microalbuminuria as a biomarker in renal and cardiovascular disease

D. de Zeeuw, S. Bakker, R. Gansevoort, 2006, Current opinion in nephrology and hypertension.

Renoprotection by blocking the RAAS in diabetic nephropathy--fact or fiction?

H. Parving, D. de Zeeuw, P. Rossing, 2006, Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association.

Irbesartan is projected to be cost and life saving in a Spanish setting for treatment of patients with type 2 diabetes, hypertension, and microalbuminuria.

P. Lapuerta, H. Parving, R. Rodby, 2005, Kidney international. Supplement.

Detecting and managing patients with type 2 diabetic kidney disease: proteinuria and cardiovascular disease.

W. Mitch, D. de Zeeuw, S. Shahinfar, 2004, Kidney international. Supplement.

Renal endothelial function is associated with the anti-proteinuric effect of ACE inhibition in 5/6 nephrectomized rats.

R. Henning, D. de Zeeuw, S. Vettoretti, 2016, American journal of physiology. Renal physiology.

Retinopathy and clinical outcomes in patients with type 2 diabetes mellitus, chronic kidney disease, and anemia

S. Solomon, M. Pfeffer, J. McMurray, 2014, BMJ Open Diabetes Research and Care.

Are angiotensin converting enzyme inhibitors superior to beta blockers in retarding progressive renal function decline?

D. de Zeeuw, P. D. de Jong, C. Stegeman, 1997, Kidney international. Supplement.

Effect of antiproteinuric treatment on the lipid profile in nondiabetic renal disease.

D. de Zeeuw, P. D. de Jong, D. Zeeuw, 1997, Contributions to nephrology.

Identifying targets to improve treatment in type 2 diabetes; the Groningen Initiative to aNalyse Type 2 diabetes Treatment (GIANTT) observational study

B. Wolffenbuttel, D. de Zeeuw, P. Denig, 2010, Pharmacoepidemiology and drug safety.

The angiotensin converting enzyme inhibitor enalapril and its effects on renal function.

A. Donker, D. de Zeeuw, P. D. de Jong, 1983, Journal of hypertension. Supplement : official journal of the International Society of Hypertension.

Treatment of idiopathic membranous nephropathy: the dilemma of who, when, and how.

D. de Zeeuw, P. D. de Jong, C. Stegeman, 1995, Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association.

Plasma Vitamin D Level and Change in Albuminuria and eGFR According to Sodium Intake.

M. M. Joosten, G. Navis, D. de Zeeuw, 2015, Clinical journal of the American Society of Nephrology : CJASN.

How to measure and monitor albuminuria in healthy toddlers?

D. de Zeeuw, H. Heerspink, S. M. van den Belt, 2018, PloS one.

Endothelial dysfunction in chronic kidney disease: determinant of susceptibility to end-organ damage and therapeutic response.

R. Henning, D. de Zeeuw, S. Vettoretti, 2006, Journal of nephrology.

Prevalence and distribution of (micro)albuminuria in toddlers.

D. de Zeeuw, E. Corpeleijn, L. K. Küpers, 2016, Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association.

Screening for microalbuminuria in the general population: a tool to detect subjects at risk for progressive renal failure in an early phase?

D. de Zeeuw, H. Hillege, P. D. de Jong, 2003, Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association.

Additive antiproteinuric effect of ACE inhibition and a low-protein diet in human renal disease.

D. de Zeeuw, R. Gansevoort, P. D. de Jong, 1995, Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association.

Angiotensin II receptor antagonist telmisartan in isolated systolic hypertension (ARAMIS) study: efficacy and safety of telmisartan 20, 40 or 80 mg versus hydrochlorothiazide 12.5 mg or placebo

D. de Zeeuw, J. Reid, A. Manolis, 2004, Journal of hypertension.

Drug dosing for renoprotection: maybe it's time for a drug efficacy-safety score?

D. de Zeeuw, Hiddo J. Lambers-Heerspink, 2009, Journal of the American Society of Nephrology : JASN.

Renal and systemic effects of continued treatment with renin inhibitor remikiren in hypertensive patients with normal and impaired renal function.

P. van Paassen, D. de Zeeuw, P. D. de Jong, 2000, Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association.

Effects of the angiotensin II antagonist losartan in hypertensive patients with renal disease.

D. de Zeeuw, R. Gansevoort, P. D. de Jong, 1994, Journal of hypertension. Supplement : official journal of the International Society of Hypertension.

Antiproteinuric efficacy of verapamil in comparison to trandolapril in non-diabetic renal disease.

D. de Zeeuw, P. D. de Jong, M. Hemmelder, 1999, Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association.

Role of proteinuria in the regulation of renal renin-angiotensin system components in unilateral proteinuric rats

R. Henning, G. Navis, D. de Zeeuw, 2003, Journal of the renin-angiotensin-aldosterone system : JRAAS.

Chronic angiotensin II infusion but not bradykinin blockade abolishes the antiproteinuric response to angiotensin-converting enzyme inhibition in established adriamycin nephrosis.

D. de Zeeuw, P. D. de Jong, G. Navis, 2000, Journal of the American Society of Nephrology : JASN.

Angiotensin-converting enzyme inhibitors and progression of nondiabetic renal disease. A meta-analysis of patient-level data.

C. Schmid, B. Brenner, A. Levey, 2001, Annals of internal medicine.

C-reactive protein and microalbuminuria differ in their associations with various domains of vascular disease.

R. Gans, D. de Zeeuw, H. Hillege, 2004, Atherosclerosis.

Creatinine-based estimation of rate of long term renal function loss in lung transplant recipients. Which method is preferable?

G. Navis, J. de Haan, D. de Zeeuw, 2000, The Journal of heart and lung transplantation : the official publication of the International Society for Heart Transplantation.

Specific Drug Delivery to the Kidney

D. de Zeeuw, D. Meijer, F. Moolenaar, 2002, Cardiovascular Drugs and Therapy.

Impact of CKD on Household Income

M. Landray, R. Collins, B. Kasiske, 2017, Kidney international reports.

C-reactive protein is associated with renal function abnormalities in a non-diabetic population.

R. Gans, D. de Zeeuw, H. Hillege, 2003, Kidney international.

Systems Biology–Derived Biomarkers to Predict Progression of Renal Function Decline in Type 2 Diabetes

G. Heinze, A. Heinzel, D. de Zeeuw, 2017, Diabetes Care.

GFR decline as an end point for clinical trials in CKD: a scientific workshop sponsored by the National Kidney Foundation and the US Food and Drug Administration.

A. Cheung, E. Lewis, J. Coresh, 2014, American journal of kidney diseases : the official journal of the National Kidney Foundation.

Sulodexide for kidney protection in type 2 diabetes patients with microalbuminuria: a randomized controlled trial.

E. Lewis, T. Berl, R. Atkins, 2011, American journal of kidney diseases : the official journal of the National Kidney Foundation.

Is the antiproteinuric effect of ACE inhibition mediated by interference in the renin-angiotensin system?

D. de Zeeuw, R. Gansevoort, P. D. de Jong, 1994, Kidney international.

Efficacy and Safety of Canagliflozin Used in Conjunction with Sulfonylurea in Patients with Type 2 Diabetes Mellitus: A Randomized, Controlled Trial

K. Mahaffey, J. Rosenstock, V. Perkovic, 2015, Diabetes Therapy.

Blood Pressure Effects of Canagliflozin and Clinical Outcomes in Type 2 Diabetes and Chronic Kidney Disease

C. Cannon, A. Levin, K. Mahaffey, 2021, Circulation.

Changes in renal function induced by ACE-inhibition in the conscious two-kidney, one-clip Goldblatt hypertensive dog.

R. Huisman, D. de Zeeuw, D. Piers, 1992, Nephron.

Do Treatment Quality Indicators Predict Cardiovascular Outcomes in Patients with Diabetes?

F. Haaijer-Ruskamp, D. de Zeeuw, P. Denig, 2013, Nederlands Tijdschrift voor Diabetologie.

Angiotensin converting enzyme insertion/deletion polymorphism and short-term renal response to ACE inhibition: role of sodium status.

G. Navis, D. de Zeeuw, P. D. de Jong, 1997, Kidney international. Supplement.

Guidelines and clinical practice at the primary level of healthcare in patients with type 2 diabetes mellitus with and without kidney disease in five European countries

G. Heinze, A. Więcek, D. de Zeeuw, 2018, Diabetes & vascular disease research.

Debate: PRO Position. Should Microalbuminuria Ever Be Considered as a Renal Endpoint in Any Clinical Trial

D. de Zeeuw, H. L. Lambers Heerspink, 2010, American Journal of Nephrology.

Predictors of fatal and nonfatal cardiovascular events in patients with type 2 diabetes mellitus, chronic kidney disease, and anemia: an analysis of the Trial to Reduce cardiovascular Events with Aranesp (darbepoetin-alfa) Therapy (TREAT).

Akshay S. Desai, H. Uno, S. Solomon, 2011, American heart journal.

Erythropoietic response and outcomes in kidney disease and type 2 diabetes.

H. Uno, S. Solomon, M. Pfeffer, 2010, The New England journal of medicine.

Are post-trial observational studies useful?

D. de Zeeuw, H. Heerspink, 2014, Journal of the American Society of Nephrology : JASN.

The International Society of Nephrology Advancing Clinical Trials (ISN-ACT) Network: current activities and future goals.

A. Levin, V. Jha, M. Jardine, 2020, Kidney international.

Empagliflozin and Progression of Kidney Disease in Type 2 Diabetes.

H. Parving, D. de Zeeuw, Hiddo J. Lambers-Heerspink, 2016, The New England journal of medicine.

Renal trials in diabetes need a platform: time for a global approach?

M. Jardine, V. Perkovic, D. de Zeeuw, 2017, The lancet. Diabetes & endocrinology.

Evaluation of measures of urinary albumin excretion.

D. de Zeeuw, S. Bakker, R. Gansevoort, 2006, American journal of epidemiology.

Additive antiproteinuric effect of angiotensin-converting enzyme inhibition and non-steroidal anti-inflammatory drug therapy: a clue to the mechanism of action.

D. de Zeeuw, P. D. de Jong, J. Heeg, 1991, Clinical science.

Effect of the Urotensin Receptor Antagonist Palosuran in Hypertensive Patients With Type 2 Diabetic Nephropathy

S. Hadjadj, G. Remuzzi, H. Krum, 2010, Hypertension.

Differential effects of enalapril and atenolol on proteinuria and renal haemodynamics in non-diabetic renal disease.

D. Zeeuw, D. de Zeeuw, P. D. de Jong, 1991, BMJ.

Proteinuria and progression of renal disease: therapeutic implications

G. Navis, D. de Zeeuw, R. Gansevoort, 1997, Current opinion in nephrology and hypertension.

A method for accurate measurement of GFR in conscious, spontaneously voiding rats.

G. Navis, D. de Zeeuw, P. D. de Jong, 1997, Kidney international.

Urine Albumin-Creatinine Ratio Versus Albumin Excretion for Albuminuria Staging: A Prospective Longitudinal Cohort Study.

D. de Zeeuw, R. Gansevoort, P. D. de Jong, 2016, American journal of kidney diseases : the official journal of the National Kidney Foundation.

Dissociation between the course of the hemodynamic and antiproteinuric effects of angiotensin I converting enzyme inhibition.

D. de Zeeuw, R. Gansevoort, P. D. de Jong, 1993, Kidney international.

Renal handling of technetium-99m DMSA: evidence for glomerular filtration and peritubular uptake.

J. Kosterink, D. de Zeeuw, M. J. de Lange, 1989, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

Prognostic value of the short-term antiproteinuric response to ACE inhibition for prediction of GFR decline in patients with nondiabetic renal disease.

G. Navis, D. de Zeeuw, P. D. de Jong, 1996, Experimental nephrology.

Does the renin-angiotensin system determine the renal and systemic hemodynamic response to sodium in patients with essential hypertension?

P. van Paassen, D. de Zeeuw, P. D. de Jong, 1996, Hypertension.

Optimizing the analysis strategy for the CANVAS Program: A prespecified plan for the integrated analyses of the CANVAS and CANVAS‐R trials

K. Mahaffey, V. Perkovic, D. Matthews, 2017, Diabetes, obesity & metabolism.

Direct vasodilating effects of the new dopaminergic agonist Z1046 in human arteries.

D. de Zeeuw, D. V. van Veldhuisen, H. Buikema, 2000, Journal of cardiovascular pharmacology.

Targeting of captopril to the kidney reduces renal angiotensin-converting enzyme activity without affecting systemic blood pressure.

D. de Zeeuw, R. Kok, D. Meijer, 2002, The Journal of pharmacology and experimental therapeutics.

The endothelin antagonist atrasentan lowers residual albuminuria in patients with type 2 diabetic nephropathy.

H. Parving, G. Remuzzi, V. Perkovic, 2014, Journal of the American Society of Nephrology : JASN.

Evaluating the Effects of Canagliflozin on Cardiovascular and Renal Events in Patients with Type 2 Diabetes and Chronic Kidney Disease According to Baseline HbA1c, Including Those with HbA1c <7%: Results From the CREDENCE Trial.

B. Zinman, C. Cannon, A. Levin, 2019, Circulation.

Inter‐individual variability in atrasentan exposure partly explains variability in kidney protection and fluid retention responses: A post hoc analysis of the SONAR trial

J. McMurray, H. Parving, G. Bakris, 2020, Diabetes, obesity & metabolism.

Canagliflozin and renal outcomes in type 2 diabetes: results from the CANVAS Program randomised clinical trials.

K. Mahaffey, V. Perkovic, D. Matthews, 2018, The lancet. Diabetes & endocrinology.

Rationale, design and baseline characteristics of the effect of canagliflozin in patients with type 2 diabetes and microalbuminuria in the Japanese population: The CANPIONE study

D. de Zeeuw, H. Heerspink, D. Koya, 2022, Diabetes, obesity & metabolism.

Early Change in Albuminuria with Canagliflozin Predicts Kidney and Cardiovascular Outcomes: A Post Hoc Analysis from the CREDENCE Trial.

A. Levin, K. Mahaffey, T. Greene, 2020, Journal of the American Society of Nephrology : JASN.

Increase in BNP in Response to Endothelin-Receptor Antagonist Atrasentan Is Associated With Incident Heart Failure.

J. McMurray, H. Parving, G. Bakris, 2022, JACC. Heart failure.

Role of elevated lecithin: cholesterol acyltransferase and cholesteryl ester transfer protein activities in abnormal lipoproteins from proteinuric patients.

D. de Zeeuw, R. Gansevoort, P. D. de Jong, 1993, Kidney international.

Coronary Myogenic Constriction Antagonizes EDHF-Mediated Dilation: Role of KCa Channels

R. Henning, D. de Zeeuw, H. Buikema, 2003, Hypertension.

Atrial natriuretic factor: its (patho)physiological significance in humans.

D. de Zeeuw, P. D. de Jong, D. Zeeuw, 1992, Kidney international.

The effects of canagliflozin on heart failure and cardiovascular death by baseline participant characteristics: Analysis of the CREDENCE trial

B. Zinman, Anubha Agarwal, M. Huffman, 2020, Diabetes, obesity & metabolism.

Atrial natriuretic factor influences renal diurnal rhythm in essential hypertension.

D. de Zeeuw, P. D. de Jong, W. Janssen, 1992, Hypertension.

Effect of human atrial natriuretic peptide on blood pressure after sodium depletion in essential hypertension.

D. de Zeeuw, P. D. de Jong, W. Janssen, 1986, British medical journal.

Individual variability in response to renin angiotensin aldosterone system inhibition predicts cardiovascular outcome in patients with type 2 diabetes: A primary care cohort study

D. de Zeeuw, H. Heerspink, M. Pena, 2018, Diabetes, obesity & metabolism.

Variability in response to albuminuria‐lowering drugs: true or random?

G. Laverman, D. de Zeeuw, H. Heerspink, 2017, British journal of clinical pharmacology.

CKD treatment: time to alter the focus to albuminuria?

D. de Zeeuw, R. Parekh, S. Soman, 2011, Advances in chronic kidney disease.

Canagliflozin and Cardiovascular and Renal Events in Type 2 Diabetes

K. Mahaffey, V. Perkovic, D. Matthews, 2017, The New England journal of medicine.

The effects of canagliflozin on gout in type 2 diabetes: a post-hoc analysis of the CANVAS Program

K. Mahaffey, A. Rodgers, V. Perkovic, 2019 .

Intracellular angiotensin II inhibits heterologous receptor stimulated Ca2+ entry.

R. Henning, D. de Zeeuw, L. Deelman, 2001, Life sciences.

The effect of CCR2 inhibitor CCX140-B on residual albuminuria in patients with type 2 diabetes and nephropathy: a randomised trial.

T. Schall, D. de Zeeuw, H. Heerspink, 2015, The lancet. Diabetes & endocrinology.

Renal vascular dysfunction precedes the development of renal damage in the hypertensive Fawn-Hooded rat.

R. Henning, D. de Zeeuw, H. Buikema, 2010, American journal of physiology. Renal physiology.

Rationale, design, and baseline characteristics of the Canagliflozin Cardiovascular Assessment Study (CANVAS)--a randomized placebo-controlled trial.

K. Mahaffey, V. Perkovic, D. Matthews, 2013, American heart journal.

Efficacy and Safety of Canagliflozin in Patients with Type 2 Diabetes and Stage 3 Nephropathy

G. Bakris, V. Perkovic, D. de Zeeuw, 2014, American Journal of Nephrology.

Immune modulation and graft protection by gene therapy in kidney transplantation.

R. Henning, D. de Zeeuw, H. van Goor, 2008, European journal of pharmacology.

Enhancement of screening tests for renovascular hypertension by angiotensin-converting enzyme inhibition.

R. Huisman, D. de Zeeuw, G. Jonker, 1993, Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association.

Titrating for antiproteinuric effect: the clue to renoprotection?

D. de Zeeuw, G. Navis, 1996, Journal of human hypertension.

NT‐proBNP by Itself Predicts Death and Cardiovascular Events in High‐Risk Patients With Type 2 Diabetes Mellitus

Akshay S. Desai, S. Solomon, M. Pfeffer, 2020, Journal of the American Heart Association.

Dual RAAS blockade has dual effects on outcome.

D. de Zeeuw, H. L. Lambers Heerspink, 2013, Nature reviews. Endocrinology.

Abstract #259 Cardiovascular and Renal Outcomes with Canagliflozin in People with Type 2 Diabetes According to Baseline use of Metformin

K. Mahaffey, M. Jardine, V. Perkovic, 2019, Endocrine Practice.

Individual Atrasentan Exposure is Associated With Long‐term Kidney and Heart Failure Outcomes in Patients With Type 2 Diabetes and Chronic Kidney Disease

J. McMurray, H. Parving, G. Bakris, 2020, Clinical pharmacology and therapeutics.

Predictors of Atrasentan-Associated Fluid Retention and Change in Albuminuria in Patients with Diabetic Nephropathy.

H. Parving, G. Remuzzi, V. Perkovic, 2015, Clinical journal of the American Society of Nephrology : CJASN.

Longitudinal Assessment of the Effect of Atrasentan on Thoracic Bioimpedance in Diabetic Nephropathy: A Randomized, Double-Blind, Placebo-Controlled Trial

D. Webb, H. Parving, G. Remuzzi, 2017, Drugs in R&D.

Pharmacokinetics of candesartan cilexetil in patients with renal or hepatic impairment.

G. Remuzzi, D. de Zeeuw, W. Kirch, 1997, Journal of human hypertension.

The role of angiotensin(1–7) in renal vasculature of the rat

R. Henning, D. de Zeeuw, L. Deelman, 2006, Journal of hypertension.

The blunting of the antiproteinuric efficacy of ACE inhibition by high sodium intake can be restored by hydrochlorothiazide.

G. Navis, D. de Zeeuw, P. D. de Jong, 1998, Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association.

Effect of Canagliflozin on Total Cardiovascular Burden in Patients With Diabetes and Chronic Kidney Disease: A Post Hoc Analysis From the CREDENCE Trial

B. Zinman, C. Cannon, A. Levin, 2022, Journal of the American Heart Association.

Symptomatic antiproteinuric treatment decreases serum lipoprotein (a) concentration in patients with glomerular proteinuria.

D. Zeeuw, D. de Zeeuw, R. Gansevoort, 1994, Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association.

Discordant effects of enalapril and lisinopril on systemic and renal hemodynamics

D. de Zeeuw, P. D. de Jong, A. J. Apperloo, 1994, Clinical pharmacology and therapeutics.

Does SGLT2 inhibition with dapagliflozin overcome individual therapy resistance to RAAS inhibition?

G. Laverman, D. de Zeeuw, H. Heerspink, 2018, Diabetes, obesity & metabolism.

Albuminuria, just a marker for cardiovascular disease, or is it more?

D. de Zeeuw, 2005, Journal of the American Society of Nephrology : JASN.

Therapeutic resistance to angiotensin converting enzyme (ACE) inhibition is related to pharmacodynamic and -kinetic factors in 5/6 nephrectomized rats.

R. Henning, D. de Zeeuw, R. P. van Dokkum, 2008, European journal of pharmacology.

Endothelial function predicts the development of renal damage after combined nephrectomy and myocardial infarction.

R. Henning, D. de Zeeuw, P. Ochodnický, 2006, Journal of the American Society of Nephrology : JASN.

D. de Zeeuw, Jingwei Li, H. J. Heerspink, 2020, JACC: Heart Failure.

Albuminuria, not only a cardiovascular/renal risk marker, but also a target for treatment?

D. de Zeeuw, 2004, Kidney international. Supplement.

Blood pressure reduction initiates the antiproteinuric effect of ACE inhibition.

D. de Zeeuw, R. Gansevoort, P. D. de Jong, 1996, Kidney international.

Blood pressure‐lowering effects of sulodexide depend on albuminuria severity: post hoc analysis of the sulodexide microalbuminuria and macroalbuminuria studies

D. de Zeeuw, H. Heerspink, L. Vogt, 2016, British journal of clinical pharmacology.

Sodium depletion enhances the antiproteinuric effect of ACE inhibition in established experimental nephrosis.

D. de Zeeuw, R. Gansevoort, P. D. de Jong, 1992, Nephron.

Diuretic Effects of Angiotensin‐Converting Enzyme Inhibition: Comparison of Low and Liberal Sodium Diet in Hypertensive Patients

A. Donker, D. de Zeeuw, P. D. de Jong, 1987, Journal of cardiovascular pharmacology.

Is the randomized controlled drug trial in Europe lagging behind the USA?

T. V. van Leeuwen, D. Grobbee, R. Tijssen, 2008, British journal of clinical pharmacology.

Endothelial dilatory function predicts individual susceptibility to renal damage in the 5/6 nephrectomized rat.

R. Henning, G. Navis, D. de Zeeuw, 2002, Journal of the American Society of Nephrology : JASN.

Urinary Albumin Excretion Predicts Cardiovascular and Noncardiovascular Mortality in General Population

Hans L Hillege, Diederick E Grobbee, Vaclav Fidler, 2002, Circulation.

Selective cyclooxygenase-2 (COX-2) inhibition reduces proteinuria in renal patients.

G. Navis, D. de Zeeuw, L. Vogt, 2008, Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association.

Letter regarding article by Klausen et al, "very low levels of microalbuminuria are associated with increased risk of coronary heart disease and death independently of renal function, hypertension, and diabetes".

D. de Zeeuw, H. Hillege, A. Brantsma, 2005, Circulation.

Low sodium diet inhibits the local counter-regulator effect of angiotensin-(1-7) on angiotensin II

R. Henning, D. de Zeeuw, W. V. van Gilst, 2004, Journal of hypertension.

Plasma calcidiol, calcitriol, and parathyroid hormone and risk of new onset heart failure in a population‐based cohort study

M. M. Joosten, R. D. de Boer, P. van der Harst, 2016, ESC heart failure.

N-terminal pro-B-type natriuretic peptide is an independent predictor of cardiovascular morbidity and mortality in the general population.

D. de Zeeuw, H. Hillege, S. Bakker, 2010, European heart journal.

Angiotensin-(1-7) is a modulator of the human renin-angiotensin system.

R. Henning, D. Zeeuw, D. de Zeeuw, 1999, Hypertension.

Association between TNF Receptors and KIM-1 with Kidney Outcomes in Early-Stage Diabetic Kidney Disease

K. Mahaffey, V. Perkovic, B. Neal, 2021, Clinical journal of the American Society of Nephrology : CJASN.

Antiproteinuric effect predicts renal protection by angiotensin-converting enzyme inhibition in rats with established adriamycin nephrosis.

D. Zeeuw, D. de Zeeuw, P. D. de Jong, 1996, Clinical science.

Intracellular angiotensin II elicits Ca2+ increases in A7r5 vascular smooth muscle cells.

R. Henning, D. de Zeeuw, J. Kok, 2001, European journal of pharmacology.

Intracellular Angiotensin II and cell growth of vascular smooth muscle cells

R. Henning, D. de Zeeuw, C. Filipeanu, 2001, British journal of pharmacology.

Contractile effects by intracellular angiotensin II via receptors with a distinct pharmacological profile in rat aorta

D. de Zeeuw, E. Brǎiloiu, C. Filipeanu, 1999, British journal of pharmacology.

Does Angiotensin (1-7) Contribute to the Antiproteinuric Effect of ACE-inhibitors?

R. Henning, D. de Zeeuw, L. Deelman, 2005, Journal of the renin-angiotensin-aldosterone system : JRAAS.

Renal targeting of captopril selectively enhances the intrarenal over the systemic effects of ACE inhibition in rats

G. Navis, D. de Zeeuw, D. Meijer, 2003, British journal of pharmacology.

Addition of AT1 blocker fails to overcome resistance to ACE inhibition in adriamycin nephrosis.

R. Henning, G. Navis, D. de Zeeuw, 2002, Kidney international.

Effects of anti-proteinuric therapy with angiotensin-converting-enzyme inhibition on renal protein catabolism in the adriamycin-induced nephrotic rat.

D. de Zeeuw, D. Meijer, P. D. de Jong, 2003, Clinical science.

High serum potassium levels after losartan can reflect more severe renal disease. Reply to Gonçalves AR, El Nahas AM [letter]

D. de Zeeuw, H. L. Lambers Heerspink, S. Roscioni, 2011, Diabetologia.

Dose of doxorubicin determines severity of renal damage and responsiveness to ACE-inhibition in experimental nephrosis.

D. Zeeuw, G. Navis, D. de Zeeuw, 1999, Journal of pharmacological and toxicological methods.

ACE polymorphism does not determine short-term renal response to ACE-inhibition in proteinuric patients.

D. de Zeeuw, R. Gansevoort, H. Scheffer, 1997, Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association.

Does the European clinical trials directive really improve clinical trial approval time?

D. Grobbee, D. de Zeeuw, H. Hillege, 2008, British journal of clinical pharmacology.

Mediators of the effects of canagliflozin on kidney protection in patients with type 2 diabetes.

K. Mahaffey, V. Perkovic, B. Neal, 2020, Kidney international.

The Canagliflozin and Renal Endpoints in Diabetes with Established Nephropathy Clinical Evaluation (CREDENCE) Study Rationale, Design, and Baseline Characteristics

B. Zinman, C. Cannon, B. Brenner, 2017, American Journal of Nephrology.

Effect of frozen storage on urinary concentration of kidney damage markers.

D. de Zeeuw, S. Bakker, R. Gansevoort, 2012, American journal of kidney diseases : the official journal of the National Kidney Foundation.

Restenosis prevalence and long-term effects on renal function after percutaneous transluminal renal angioplasty.

A. Donker, D. de Zeeuw, P. D. de Jong, 1986, Nephron.

Effect of lowering blood pressure on cardiovascular events and mortality in patients on dialysis: a systematic review and meta-analysis of randomised controlled trials

D. Grobbee, M. Jardine, V. Perkovic, 2009, The Lancet.

Urinary albumin excretion is associated with renal functional abnormalities in a nondiabetic population.

D. Zeeuw, D. de Zeeuw, H. Hillege, 2000, Journal of the American Society of Nephrology : JASN.

The antiproteinuric effects of blood pressure-lowering agents: differences between nondiabetics and diabetics.

D. de Zeeuw, P. D. de Jong, J. Heeg, 1992, Journal of cardiovascular pharmacology.

The antiproteinuric effect of antihypertensive agents in diabetic nephropathy.

D. de Zeeuw, R. Gansevoort, P. D. de Jong, 1992, Archives of internal medicine.

Factors influencing serum cystatin C levels other than renal function and the impact on renal function measurement.

D. Spiegelman, G. Curhan, D. de Zeeuw, 2004, Kidney international.

ACE Inhibition Preserves Heparan Sulfate Proteoglycans in the Glomerular Basement Membrane of Rats with Established Adriamycin Nephropathy

D. Zeeuw, D. de Zeeuw, P. D. de Jong, 2000, Nephron Experimental Nephrology.

Rationale, design and baseline characteristics of the CANagliflozin cardioVascular Assessment Study–Renal (CANVAS‐R): A randomized, placebo‐controlled trial

K. Mahaffey, V. Perkovic, D. Matthews, 2017, Diabetes, obesity & metabolism.

Canagliflozin for Primary and Secondary Prevention of Cardiovascular Events

K. Mahaffey, V. Perkovic, D. Matthews, 2017, Circulation.

Cardiorenal end points in a trial of aliskiren for type 2 diabetes.

Nish Chaturvedi, Akshay S. Desai, Marc A Pfeffer, 2012, The New England journal of medicine.

Excessive Urinary Albumin Levels Are Associated With Future Cardiovascular Mortality in Postmenopausal Women

D. Grobbee, J. Sixma, D. de Zeeuw, 2001, Circulation.

The antihypertensive and renal effects of angiotensin II receptor antagonists: remaining questions.

D. de Zeeuw, R. Gansevoort, 2000, Current opinion in nephrology and hypertension.

Comparison of urine collection methods for albuminuria assessment in young children.

D. de Zeeuw, H. Heerspink, S. M. van den Belt, 2016, Clinica chimica acta; international journal of clinical chemistry.

Prediction of the effect of atrasentan on renal and heart failure outcomes based on short-term changes in multiple risk markers

H. Parving, G. Remuzzi, V. Perkovic, 2016, European journal of preventive cardiology.

Construct and concurrent validity of a patient-reported adverse drug event questionnaire: a cross-sectional study

F. Haaijer-Ruskamp, D. de Zeeuw, P. Denig, 2014, Health and Quality of Life Outcomes.

Efficacy of a novel inhibitor of vascular adhesion protein-1 in reducing albuminuria in patients with diabetic kidney disease (ALBUM): a randomised, placebo-controlled, phase 2 trial.

G. Bakris, V. Perkovic, M. Nangaku, 2018, The lancet. Diabetes & endocrinology.

Systemic gene therapy with interleukin-13 attenuates renal ischemia-reperfusion injury.

R. Henning, D. Zeeuw, D. de Zeeuw, 2008, Kidney international.

Angiotensin Converting Enzyme Inhibition Improves Diagnostic Procedures for Renovascular Hypertension in Dogs

R. Huisman, D. de Zeeuw, H. Beekhuis, 1988, Hypertension.

Atrial natriuretic peptide-induced decreases in renal blood flow in man: implications for the natriuretic mechanism.

D. de Zeeuw, P. D. de Jong, W. Janssen, 1989, Clinical science.

Comment on: Ekinci et al. Dietary Salt Intake and Mortality in Patients With Type 2 Diabetes. Diabetes Care 2011;34:703–709

G. Navis, A. Kwakernaak, D. de Zeeuw, 2011, Diabetes Care.

Renal targeting of captopril using captopril-lysozyme conjugate enhances its antiproteinuric effect in adriamycin-induced nephrosis

R. Henning, D. de Zeeuw, R. Kok, 2004, Journal of the renin-angiotensin-aldosterone system : JRAAS.

Enhanced transduction of fibroblasts in transplanted kidney with an adenovirus having an RGD motif in the HI loop.

M. Rots, R. Henning, D. de Zeeuw, 2006, Kidney international.

Albuminuria, a Therapeutic Target for Cardiovascular Protection in Type 2 Diabetic Patients With Nephropathy

B. Brenner, H. Parving, G. Remuzzi, 2004, Circulation.

Adenovirus‐mediated interleukin‐13 gene therapy attenuates acute kidney allograft injury

R. Henning, D. de Zeeuw, H. van Goor, 2007, The journal of gene medicine.

Restenosis of the renal artery after percutaneous transluminal renal angioplasty: an inevitable outcome?

D. de Zeeuw, P. D. de Jong, K. Kuiper, 1983, Proceedings of the European Dialysis and Transplant Association. European Dialysis and Transplant Association.

The effects of lowering LDL cholesterol with simvastatin plus ezetimibe in patients with chronic kidney disease (Study of Heart and Renal Protection): a randomised placebo-controlled trial

M. Landray, R. Collins, B. Kasiske, 2011, The Lancet.

An acute fall in estimated glomerular filtration rate during treatment with losartan predicts a slower decrease in long-term renal function.

Merlin C. Thomas, B. Brenner, H. Parving, 2011, Kidney international.

Semi-micro method for the determination of cation flux rate constants in erythrocytes.

R. Huisman, D. de Zeeuw, T. Tepper, 1985, Clinica chimica acta; international journal of clinical chemistry.

Diagnostic use of angiotensin converting enzyme inhibitors in radioisotope evaluation of unilateral renal artery stenosis.

D. de Zeeuw, P. D. de Jong, D. Piers, 1989, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

Low Sodium Modifies the Vascular Effects of Angiotensin-Converting Enzyme Inhibitor Therapy in Healthy Rats

G. Navis, D. de Zeeuw, H. Buikema, 2004, Journal of Pharmacology and Experimental Therapeutics.

Albuminuria assessed from first-morning-void urine samples versus 24-hour urine collections as a predictor of cardiovascular morbidity and mortality.

D. de Zeeuw, S. Bakker, R. Gansevoort, 2008, American journal of epidemiology.

The serum lathosterol to cholesterol ratio, an index of cholesterol synthesis, is not elevated in patients with glomerular proteinuria and is not associated with improvement of hyperlipidemia in response to antiproteinuric treatment.

D. de Zeeuw, R. Gansevoort, P. D. de Jong, 1996, Metabolism: clinical and experimental.

Immune response to two different hepatitis B vaccines in haemodialysis patients: a 2-year follow-up.

D. de Zeeuw, C. Gips, D. Zeeuw, 1985, Nephron.

Alkalinization of urine samples preserves albumin concentrations during prolonged frozen storage in patients with diabetes mellitus

D. de Zeeuw, R. Gansevoort, H. L. Lambers Heerspink, 2009, Diabetic medicine : a journal of the British Diabetic Association.

Urinary pH affects albumin concentrations after prolonged frozen storage.

D. de Zeeuw, H. Heerspink, S. Bakker, 2007, Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association.

Baseline characteristics and enrichment results from the SONAR trial

J. McMurray, H. Parving, G. Bakris, 2018, Diabetes, obesity & metabolism.

The effects of atrasentan on urinary metabolites in patients with type 2 diabetes and nephropathy

H. Parving, G. Remuzzi, V. Perkovic, 2017, Diabetes, obesity & metabolism.

Large Between-Patient Variability in eGFR Decline Before Clinical Trial Enrollment and Impact on Atrasentan's Efficacy - A Post-Hoc Analysis From the SONAR Trial.

H. Parving, C. Wanner, G. Laverman, 2021, Journal of the American Society of Nephrology : JASN.

Effects of enalapril on blood pressure and renal haemodynamics in essential hypertension.

A. Donker, D. de Zeeuw, P. D. de Jong, 1983, Proceedings of the European Dialysis and Transplant Association. European Dialysis and Transplant Association.

Early, but not late therapy with a vasopressin V1a-antagonist ameliorates the development of renal damage after 5/6 nephrectomy

R. Henning, D. de Zeeuw, R. P. van Dokkum, 2006, Journal of the renin-angiotensin-aldosterone system : JRAAS.

Drug delivery to the kidneys and the bladder with the low molecular weight protein lysozyme.

D. Meijer, D. de Zeeuw, R. Kok, 1998, Renal failure.

Organic Anion Transporter Gene Variants Associated With Plasma Exposure and Long‐Term Response to Atrasentan in Patients With Diabetic Kidney Disease

J. McMurray, H. Parving, G. Bakris, 2022, Clinical pharmacology and therapeutics.

Urinary prostaglandins in sickle cell nephropathy: a defect in 9-ketoreductase activity?

A. Donker, D. de Zeeuw, P. D. de Jong, 1984, Clinical nephrology.

The influence of indomethacin on renal concentrating and diluting capacity in sickle cell nephropathy.

L. de Jong-van den Berg, A. Donker, D. de Zeeuw, 1982, Clinical science.

D. de Zeeuw, H. Hillege, P. D. de Jong, 2000, Annals of Internal Medicine.

Hypertension and renal disease: role of microalbuminuria.

D. de Zeeuw, P. D. de Jong, W. Janssen, 1996, Journal of hypertension. Supplement : official journal of the International Society of Hypertension.

Angiotensin converting enzyme inhibitors and progressive renal insufficiency. Current experience and future directions.

D. de Zeeuw, S. Anderson, W. Keane, 1989, Annals of internal medicine.

Effect of a Reduction in Uric Acid on Renal Outcomes During Losartan Treatment: A Post Hoc Analysis of the Reduction of Endpoints in Non-Insulin-Dependent Diabetes Mellitus With the Angiotensin II Antagonist Losartan Trial

B. Brenner, H. Parving, D. Grobbee, 2011, Hypertension.

Proteinuria, a target for renoprotection in patients with type 2 diabetic nephropathy: lessons from RENAAL.

Zhongxin Zhang, Giuseppe Remuzzi, B. Brenner, 2004, Kidney international.

Long-term renal outcome after lung transplantation is predicted by the 1-month postoperative renal function loss.

D. de Zeeuw, P. D. de Jong, C. Stegeman, 2000, Transplantation.

Unmet need in renal protection--do we need a more comprehensive approach?

D. de Zeeuw, 2011, Contributions to nephrology.

Bioanalysis of captopril: two sensitive high-performance liquid chromatographic methods with pre- or postcolumn fluorescent labeling.

D. de Zeeuw, R. Kok, D. Meijer, 1997, Journal of chromatography. B, Biomedical sciences and applications.

POTENTIALS AND LIMITATIONS OF THE LOW-MOLECULAR-WEIGHT PROTEIN LYSOZYME AS A CARRIER FOR RENAL DRUG TARGETING

D. de Zeeuw, D. Meijer, P. M. deVries, 2001, Renal failure.

Bardoxolone methyl in type 2 diabetes and stage 4 chronic kidney disease.

J. McMurray, H. Parving, G. Remuzzi, 2013, The New England journal of medicine.

Reduction of urinary protein and prostaglandin E2 excretion in the nephrotic syndrome by non-steroidal anti-inflammatory drugs.

A. Donker, D. de Zeeuw, P. D. de Jong, 1986, Clinical nephrology.

Optimal blood pressure control and antihypertensive regimens in hypertensive renal disease: the potential of exploring the mechanisms of response variability

G. Navis, D. de Zeeuw, M. J. Kocks, 2002, Current opinion in nephrology and hypertension.

Diabetic Kidney Disease– A clinical update from Kidney Disease: Improving Global Outcomes (KDIGO)

B. Kasiske, W. So, C. Wanner, 2014, Kidney international.

Dapagliflozin a glucose-regulating drug with diuretic properties in subjects with type 2 diabetes

D. de Zeeuw, H. Heerspink, D. Zeeuw, 2013, Diabetes, obesity & metabolism.

Moderation of dietary sodium potentiates the renal and cardiovascular protective effects of angiotensin receptor blockers.

H. Parving, J. Lewis, G. Navis, 2012, Kidney international.

Effect of Canagliflozin on Renal and Cardiovascular Outcomes across Different Levels of Albuminuria: Data from the CANVAS Program.

K. Mahaffey, M. Jardine, V. Perkovic, 2019, Journal of the American Society of Nephrology : JASN.

Cardiovascular and Renal Outcomes With Canagliflozin According to Baseline Kidney Function

K. Mahaffey, G. Bakris, M. Jardine, 2018, Circulation.

Efficacy and Safety of Canagliflozin, an Inhibitor of Sodium–Glucose Cotransporter 2, When Used in Conjunction With Insulin Therapy in Patients With Type 2 Diabetes

K. Mahaffey, V. Perkovic, D. Matthews, 2014, Diabetes Care.

Effects of Fosinopril and Pravastatin on Cardiovascular Events in Subjects With Microalbuminuria

Hans L. Hillege, Folkert W. Asselbergs, Adriaan A. Voors, 2004, Circulation.

Biochemical risk markers: a novel area for better prediction of renal risk?

R. Gans, D. de Zeeuw, H. Hillege, 2005, Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association.

Angiotensin II receptor antagonist treatment lowers plasma total and very low + low density lipoprotein cholesterol in Type 1 diabetic patients with albuminuria without affecting plasma cholesterol esterification and cholesteryl ester transfer.

D. de Zeeuw, P. D. de Jong, A. van Tol, 2000, Diabetic medicine : a journal of the British Diabetic Association.

Improving clinical trial efficiency by biomarker-guided patient selection

D. Grobbee, D. de Zeeuw, H. Heerspink, 2014, Trials.

Sulodexide fails to demonstrate renoprotection in overt type 2 diabetic nephropathy.

E. Lewis, T. Berl, J. Chan, 2012, Journal of the American Society of Nephrology : JASN.

Association between individual cholesterol and proteinuria response and exposure to atorvastatin or rosuvastatin

D. de Zeeuw, H. Heerspink, J. Stevens, 2019, Diabetes, obesity & metabolism.

Regulation of [Ca2+]i homeostasis in MRP1 overexpressing cells

D. de Zeeuw, J. Kok, R. Veldman, 2000, FEBS letters.

Normalization of aortic function during arousal episodes in the hibernating ground squirrel.

S. Daan, R. Henning, D. de Zeeuw, 2002, Life sciences.

Measurement of glomerular charge selectivity in non-diabetic renal disease.

D. de Zeeuw, P. D. de Jong, M. Hemmelder, 1997, Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association.

Can continuous intraperitoneal infusion of 125I-iothalamate and 131I-hippuran be used for measurement of GFR in conscious rats?

D. de Zeeuw, P. D. de Jong, P. de Vries, 1998, Renal failure.

Determination of dopaminergic prodrugs by high-performance liquid chromatography followed by post-column ion-pair extraction.

D. de Zeeuw, D. Meijer, D. Dijkstra, 1997, Journal of chromatography. B, Biomedical sciences and applications.

Highly sensitive measurement of indomethacin using a high-performance liquid chromatographic technique combined with post-column in-line hydrolysis.

D. de Zeeuw, D. Brater, J. Leinfelder, 1986, Journal of chromatography.

The Abnormal Renal Vasodilator Response to D1-Like Receptor Stimulation in Conscious SHR Can Be Normalized by AT1 Blockade

G. Navis, D. de Zeeuw, P. D. de Jong, 2004, Journal of cardiovascular pharmacology.

D2-Like Receptor Stimulation Decreases Effective Renal Plasma Flow and Glomerular Filtration Rate in Spontaneously Hypertensive Rats

G. Navis, D. de Zeeuw, P. D. de Jong, 2002, Journal of cardiovascular pharmacology.

Impaired renal vascular response to a D1-like receptor agonist but not to an ACE inhibitor in conscious spontaneously hypertensive rats.

D. de Zeeuw, P. D. de Jong, P. de Vries, 1999, Journal of cardiovascular pharmacology.

Novel anti-inflammatory drugs for the treatment of diabetic kidney disease

D. de Zeeuw, H. Heerspink, 2016, Diabetologia.

ISN Nexus 2016 Symposia: Translational Immunology in Kidney Disease—The Berlin Roadmap

A. Levin, B. Rovin, G. Remuzzi, 2016, Kidney International Reports.

Renal function and risk for cardiovascular events in type 2 diabetic patients with hypertension: the RENAAL and LIFE studies

B. Brenner, H. Parving, G. Remuzzi, 2007, Journal of hypertension.

The risk of developing end-stage renal disease in patients with type 2 diabetes and nephropathy: the RENAAL study.

B. Brenner, J. McGill, R. Toto, 2003, Kidney international.

Proteinuria as a modifiable risk factor for the progression of non-diabetic renal disease.

C. Schmid, A. Levey, G. Remuzzi, 2001, Kidney international.

Effects of lowering LDL cholesterol on progression of kidney disease.

M. Landray, A. Levin, J. Craig, 2014, Journal of the American Society of Nephrology : JASN.

A trial of darbepoetin alfa in type 2 diabetes and chronic kidney disease.

S. Solomon, M. Pfeffer, J. McMurray, 2009, The New England journal of medicine.

Effect of SGLT2 Inhibitors on Stroke and Atrial Fibrillation in Diabetic Kidney Disease

C. Cannon, A. Levin, K. Mahaffey, 2021, Stroke.

Microalbuminuria: target for renoprotective therapy PRO.

D. de Zeeuw, H. L. Lambers Heerspink, S. Roscioni, 2014, Kidney international.

Canagliflozin and Heart Failure in Type 2 Diabetes Mellitus

S. Solomon, K. Mahaffey, G. Figtree, 2018, Circulation.

Bilirubin and Progression of Nephropathy in Type 2 Diabetes: A Post Hoc Analysis of RENAAL With Independent Replication in IDNT

J. Lewis, G. Navis, D. de Zeeuw, 2014, Diabetes.

Renal function, neurohormonal activation, and survival in patients with chronic heart failure.

A. Charlesworth, J. Hampton, D. de Zeeuw, 2000, Circulation.

Prognostic imaging biomarkers for diabetic kidney disease (iBEAt): study protocol

M. Gilchrist, S. Sourbron, I. Teh, 2020, BMC Nephrology.

Relevance of correction for drift and day-to-day variation in cystatin C measurement: a post-hoc analysis of the PREVEND cohort, with independent replication in the ESTHER cohort

H. Brenner, D. Rothenbacher, B. Schöttker, 2015, Clinical chemistry and laboratory medicine.

Smoking and Adverse Outcomes in Patients With CKD: The Study of Heart and Renal Protection (SHARP)

M. Landray, R. Collins, B. Kasiske, 2016, American journal of kidney diseases : the official journal of the National Kidney Foundation.

Cardiovascular and renal outcome in subjects with K/DOQI stage 1-3 chronic kidney disease: the importance of urinary albumin excretion.

D. de Zeeuw, H. Hillege, S. Bakker, 2008, Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association.

Effects of nonsteroidal anti-inflammatory drugs on proteinuria.

A. Donker, D. de Zeeuw, P. D. de Jong, 1986, The American journal of medicine.

A central body fat distribution is related to renal function impairment, even in lean subjects.

G. Navis, D. de Zeeuw, P. D. de Jong, 2003, American journal of kidney diseases : the official journal of the National Kidney Foundation.

Longitudinal relationship between albuminuria in infancy and childhood

D. de Zeeuw, H. Heerspink, H. Verkade, 2023, Pediatric Nephrology.

Relative risks of Chronic Kidney Disease for mortality and End Stage Renal Disease across races is similar

B. Astor, J. Coresh, A. Levin, 2014, Kidney international.

Volume homeostasis, angiotensin converting enzyme inhibition, and lithium therapy.

D. de Zeeuw, P. D. de Jong, G. Navis, 1989, American Journal of Medicine.

Indomethacin secretion in the isolated perfused proximal straight rabbit tubule. Evidence for two parallel transport mechanisms.

H. Jacobson, D. de Zeeuw, D. Brater, 1988, The Journal of clinical investigation.

Lowering LDL cholesterol reduces cardiovascular risk independently of presence of inflammation

M. Landray, R. Collins, B. Kasiske, 2017, Kidney international.

C-Reactive Protein Modifies the Relationship Between Blood Pressure and Microalbuminuria

R. Gans, J. Burgerhof, D. de Zeeuw, 2004, Hypertension.

Discontinuation of RAAS Inhibition in Children with Advanced CKD.

D. de Zeeuw, H. Heerspink, J. Bacchetta, 2020, Clinical journal of the American Society of Nephrology : CJASN.

Early Proteinuria Lowering by Angiotensin-Converting Enzyme Inhibition Predicts Renal Survival in Children with CKD.

D. de Zeeuw, H. Heerspink, F. Schaefer, 2018, Journal of the American Society of Nephrology : JASN.

Micro-HPLC and transfer techniques for directly measuring drug (indomethacin) transport across the isolated perfused renal proximal straight tubule.

H. Jacobson, D. de Zeeuw, D. Brater, 1988, Journal of Pharmacological Methods.

Risk factors for heart failure in patients with type 2 diabetes mellitus and stage 4 chronic kidney disease treated with bardoxolone methyl.

J. McMurray, G. Bakris, J. Wittes, 2014, Journal of cardiac failure.

Progression of Chronic Kidney Disease: The Role of Blood Pressure Control, Proteinuria, and Angiotensin-Converting Enzyme Inhibition: A Patient-Level Meta-Analysis

Christopher H Schmid, Giuseppe Maschio, C. Schmid, 2003, Annals of Internal Medicine.

Systemic factors are involved in the pathogenesis of proteinuria-induced glomerulosclerosis in adriamycin nephrotic rats.

G. Navis, D. de Zeeuw, P. D. de Jong, 1999, Journal of the American Society of Nephrology : JASN.

Additive antiproteinuric effect of the NSAID indomethacin and the ACE inhibitor lisinopril.

D. de Zeeuw, P. D. de Jong, J. Heeg, 1990, American journal of nephrology.

Drug-induced changes in renal hippurate clearance as a measure of renal blood flow.

R. Huisman, D. de Zeeuw, P. D. de Jong, 1995, Kidney international.

Increased serum potassium affects renal outcomes: a post hoc analysis of the Reduction of Endpoints in NIDDM with the Angiotensin II Antagonist Losartan (RENAAL) trial

B. Brenner, H. Parving, D. Grobbee, 2010, Diabetologia.

Nephroptosis and kidney function.

A. Donker, D. de Zeeuw, E. Kremer, 1978, Nephron.

Nephrotic syndrome preceding Hodgkin's disease by 42 months.

R. Huisman, D. de Zeeuw, P. D. de Jong, 1986, Clinical nephrology.

Risk scores for predicting outcomes in patients with type 2 diabetes and nephropathy: the RENAAL study.

Zhongxin Zhang, Giuseppe Remuzzi, Janet B McGill, 2006, Clinical journal of the American Society of Nephrology : CJASN.

Prognosis of renal manifestations of Henoch-Schönlein syndrome in adults. A retrospective study of 18 patients.

D. de Zeeuw, P. Hoedemaeker, J. R. Beukhof, 1986, The Netherlands journal of medicine.

Antiproteinuric effect of naproxen and indomethacin. A double-blind crossover study.

A. Donker, D. de Zeeuw, P. D. de Jong, 1985, American journal of nephrology.

Individual titration for maximal blockade of the renin-angiotensin system in proteinuric patients: a feasible strategy?

G. Navis, D. de Zeeuw, Dick de Zeeuw, 2005, Journal of the American Society of Nephrology : JASN.

Pharmacological blood pressure lowering for primary and secondary prevention of cardiovascular disease across different levels of blood pressure: an individual participant-level data meta-analysis

R. Collins, B. Davis, M. Pfeffer, 2021, The Lancet.

Age-stratified and blood-pressure-stratified effects of blood-pressure-lowering pharmacotherapy for the prevention of cardiovascular disease and death: an individual participant-level data meta-analysis

R. Collins, B. Davis, M. Pfeffer, 2021, The Lancet.

LDL cholesterol in CKD--to treat or not to treat?

D. de Zeeuw, Z. Massy, 2013, Kidney international.

Antihypertensive treatment and risk of cancer: an individual participant data meta-analysis

B. Davis, R. Holman, C. Bulpitt, 2021, The Lancet. Oncology.

Blood pressure-lowering treatment for prevention of major cardiovascular diseases in people with and without type 2 diabetes: an individual participant-level data meta-analysis

B. Davis, R. Holman, P. Whelton, 2022, The lancet. Diabetes & endocrinology.

Rationale--Trial to Reduce Cardiovascular Events with Aranesp Therapy (TREAT): evolving the management of cardiovascular risk in patients with chronic kidney disease.

S. Solomon, M. Pfeffer, J. McMurray, 2005, American heart journal.

Sample dilution: a methodological pitfall in the measurement of tissue but not serum ace-activity.

D. de Zeeuw, P. D. de Jong, W. V. van Gilst, 1998, Journal of pharmacological and toxicological methods.

Statins: cholesterol, blood pressure and beyond.

R. Henning, D. de Zeeuw, R. P. van Dokkum, 2002, Journal of hypertension.

The association between atherosclerotic risk factors and renal function in the general population.

J. Burgerhof, D. de Zeeuw, H. Hillege, 2005, Kidney international.

Role of the endothelin-1 gene locus for renal impairment in the general nondiabetic population.

T. Niu, D. de Zeeuw, H. Hillege, 2003, Journal of the American Society of Nephrology : JASN.

Baseline characteristics in the Bardoxolone methyl EvAluation in patients with Chronic kidney disease and type 2 diabetes mellitus: the Occurrence of renal eveNts (BEACON) trial.

J. McMurray, H. Parving, G. Remuzzi, 2013, Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association.

Drug-induced changes in risk/biomarkers and their relationship with renal and cardiovascular long-term outcome in patients with diabetes.

D. de Zeeuw, H. L. Lambers Heerspink, P. Smink, 2011, Clinical chemistry.

The kidney in type 2 diabetes therapy.

D. de Zeeuw, H. Heerspink, 2011, The review of diabetic studies : RDS.

The economic benefits of preventing end-stage renal disease in patients with type 2 diabetes mellitus.

M. Postma, D. de Zeeuw, 2009, Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association.

Dual renin-angiotensin system blockade and kidney disease.

S. Solomon, M. Pfeffer, J. McMurray, 2009, Journal of the American College of Cardiology.

Aliskiren Trial in Type 2 Diabetes Using Cardio-Renal Endpoints (ALTITUDE): rationale and study design.

S. Solomon, M. Pfeffer, J. McMurray, 2009, Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association.

The impact of canagliflozin on the risk of neuropathy events: a post-hoc exploratory analysis of the CREDENCE trial.

B. Zinman, A. Levin, K. Mahaffey, 2022, Diabetes & metabolism.

Delta9-tetrahydrocannabinol activates [Ca2+]i increases partly sensitive to capacitative store refilling.

D. de Zeeuw, C. Filipeanu, S. Nelemans, 1997, European journal of pharmacology.

Between-patient differences in the renal response to renin-angiotensin system intervention: clue to optimising renoprotective therapy?

G. Navis, G. Laverman, D. de Zeeuw, 2002, Journal of the renin-angiotensin-aldosterone system : JRAAS.

Specific delivery of captopril to the kidney with the prodrug captopril-lysozyme.

D. de Zeeuw, D. Meijer, F. Moolenaar, 1999, The Journal of pharmacology and experimental therapeutics.

Quantification of renal low-molecular-weight protein handling in the intact rat.

D. de Zeeuw, D. Meijer, A. V. van Zanten, 1993, Kidney international.

Need for better diabetes treatment for improved renal outcome.

D. de Zeeuw, P. Rossing, 2011, Kidney international. Supplement.

Metabolic syndrome: a fata morgana?

D. de Zeeuw, S. Bakker, R. Gansevoort, 2006, Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association.

An initial reduction in serum uric acid during angiotensin receptor blocker treatment is associated with cardiovascular protection: a post-hoc analysis of the RENAAL and IDNT trials

T. Berl, G. Laverman, D. de Zeeuw, 2012, Journal of hypertension.

Renal and cardio-protective effects of direct renin inhibition: a systematic literature review

V. Perkovic, D. de Zeeuw, H. L. Lambers Heerspink, 2009, Journal of hypertension.

Screening and monitoring for albuminuria: the performance of the HemoCue point-of-care system.

D. de Zeeuw, S. Bakker, R. Gansevoort, 2008, Kidney international.

Baseline characteristics in the Trial to Reduce Cardiovascular Events With Aranesp Therapy (TREAT).

H. Uno, S. Solomon, M. Pfeffer, 2009, American journal of kidney diseases : the official journal of the National Kidney Foundation.

New insights from SONAR indicate adding sodium glucose co-transporter 2 inhibitors to an endothelin receptor antagonist mitigates fluid retention and enhances albuminuria reduction.

D. de Zeeuw, H. Heerspink, D. Kohan, 2020, Kidney international.

Gender differences in predictors of the decline of renal function in the general population.

D. de Zeeuw, S. Bakker, R. Gansevoort, 2008, Kidney international.

Time for clinical decision support systems tailoring individual patient therapy to improve renal and cardiovascular outcomes in diabetes and nephropathy

D. de Zeeuw, H. Heerspink, 2020, Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association.

Cost-effectiveness of lipid lowering with statins and ezetimibe in chronic kidney disease

M. Landray, R. Collins, B. Kasiske, 2019, Kidney international.

Cost-effectiveness of Simvastatin plus Ezetimibe for Cardiovascular Prevention in CKD: Results of the Study of Heart and Renal Protection (SHARP)

M. Landray, R. Collins, B. Kasiske, 2016, American journal of kidney diseases : the official journal of the National Kidney Foundation.

Enalapril and the Kidney: Renal Vasodilation and Natriuresis Due to the Inhibition of Angiotensin II Formation

D. de Zeeuw, P. D. de Jong, G. Navis, 1986, Journal of cardiovascular pharmacology.

Plasma proteomics classifiers improve risk prediction for renal disease in patients with hypertension or type 2 diabetes

G. Heinze, A. Heinzel, J. Jankowski, 2015, Journal of hypertension.

Prognostic clinical and molecular biomarkers of renal disease in type 2 diabetes.

B. Mayer, H. Mischak, J. Jankowski, 2015, Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association.

Renal hyperfiltration defined by high estimated glomerular filtration rate: A risk factor for cardiovascular disease and mortality

A. Ortiz, D. de Zeeuw, B. Afşar, 2019, Diabetes, obesity & metabolism.

Reasons for hospitalizations in patients with type 2 diabetes in the CANVAS programme: A secondary analysis

K. Mahaffey, M. Jardine, V. Perkovic, 2021, Diabetes, obesity & metabolism.

Effects of canagliflozin on myocardial infarction: a post hoc analysis of the CANVAS Program and CREDENCE trial.

Mark D. Huffman, M. Huffman, K. Mahaffey, 2021, Cardiovascular research.

Clinical outcomes with canagliflozin according to baseline body mass index: results from post hoc analyses of the CANVAS Program

K. Mahaffey, V. Perkovic, D. Matthews, 2019, Diabetes, obesity & metabolism.

Efficacy and safety of canagliflozin when used in conjunction with incretin‐mimetic therapy in patients with type 2 diabetes

K. Mahaffey, V. Perkovic, D. Matthews, 2016, Diabetes, obesity & metabolism.

Urinary albumin excretion as a predictor of the development of hypertension in the general population.

D. de Zeeuw, S. Bakker, R. Gansevoort, 2006, Journal of the American Society of Nephrology : JASN.

Relative and Absolute Risk Reductions in Cardiovascular and Kidney Outcomes With Canagliflozin Across KDIGO Risk Categories: Findings From the CANVAS Program.

K. Mahaffey, M. Jardine, V. Perkovic, 2020, American journal of kidney diseases : the official journal of the National Kidney Foundation.

Omics-bioinformatics in the context of clinical data.

Gert Mayer, Georg Heinze, Harald Mischak, 2011, Methods in molecular biology.

What predicts progression and regression of urinary albumin excretion in the nondiabetic population?

D. de Zeeuw, S. Bakker, R. Gansevoort, 2007, Journal of the American Society of Nephrology : JASN.

Rationale and protocol of the Study Of diabetic Nephropathy with AtRasentan (SONAR) trial: A clinical trial design novel to diabetic nephropathy

J. McMurray, H. Parving, G. Bakris, 2018, Diabetes, obesity & metabolism.

Kidney and Cardiovascular Effects of Canagliflozin According to Age and Sex: A Post Hoc Analysis of the CREDENCE Randomized Clinical Trial.

B. Zinman, A. Levin, K. Mahaffey, 2023, American journal of kidney diseases : the official journal of the National Kidney Foundation.

Initial Angiotensin Receptor Blockade–Induced Decrease in Albuminuria Is Associated With Long-Term Renal Outcome in Type 2 Diabetic Patients With Microalbuminuria

H. Parving, D. de Zeeuw, S. Bakker, 2011, Diabetes Care.

Influence of age on the prognostic value of mid-regional pro-adrenomedullin in the general population

R. D. de Boer, P. van der Harst, D. de Zeeuw, 2012, Heart.

Predictors of congestive heart failure after treatment with an endothelin receptor antagonist.

D. de Zeeuw, H. L. Lambers Heerspink, G. Viberti, 2014, Clinical journal of the American Society of Nephrology : CJASN.

Role of patient factors in therapy resistance to antiproteinuric intervention in nondiabetic and diabetic nephropathy.

H. Parving, G. Navis, D. de Zeeuw, 2000, Kidney international. Supplement.

Predictors of Progression in Albuminuria in the General Population: Results from the PREVEND Cohort

D. de Zeeuw, S. Bakker, R. Gansevoort, 2013, PloS one.

Baseline characteristics in the Aliskiren Trial in Type 2 Diabetes Using Cardio-Renal Endpoints (ALTITUDE)

M. Pfeffer, J. McMurray, B. Brenner, 2012, Journal of the renin-angiotensin-aldosterone system : JRAAS.

A short-term antihypertensive treatment-induced fall in glomerular filtration rate predicts long-term stability of renal function.

D. de Zeeuw, P. D. de Jong, A. J. Apperloo, 1997, Kidney international.

Effect of Losartan on Microalbuminuria in Normotensive Patients with Type 2 Diabetes Mellitus

D. de Zeeuw, S. Lamberts, R. Ouwendijk, 2003, Annals of Internal Medicine.

Albuminuria and blood pressure, independent targets for cardioprotective therapy in patients with diabetes and nephropathy: a post hoc analysis of the combined RENAAL and IDNT trials.

T. Berl, H. Parving, G. Remuzzi, 2011, European heart journal.

Number and frequency of albuminuria measurements in clinical trials in diabetic nephropathy.

H. Parving, D. de Zeeuw, H. Heerspink, 2015, Clinical journal of the American Society of Nephrology : CJASN.

Comparison of midregional pro-A-type natriuretic peptide and the N-terminal pro-B-type natriuretic peptide for predicting mortality and cardiovascular events.

D. de Zeeuw, S. Bakker, R. Gansevoort, 2012, Clinical chemistry.

The losartan renal protection study — rationale, study design and baseline characteristics of RENAAL (Reduction of Endpoints in NIDDM with the Angiotensin II Antagonist Losartan)

M. Schluchter, B. Brenner, J. McGill, 2000, Journal of the renin-angiotensin-aldosterone system : JRAAS.

A population-based screening for microalbuminuria among relatives of CKD patients: the Kidney Evaluation and Awareness Program in Sheffield (KEAPS).

A. Bello, D. de Zeeuw, J. Peters, 2008, American journal of kidney diseases : the official journal of the National Kidney Foundation.

A review of methods used in assessing non-serious adverse drug events in observational studies among type 2 diabetes mellitus patients

Petra Denig, F. Haaijer-Ruskamp, D. de Zeeuw, 2011, Health and quality of life outcomes.

Pharmacokinetics and pharmacodynamics of candesartan cilexetil in patients with normal to severely impaired renal function

D. de Zeeuw, P. D. de Jong, A. Woittiez, 1999, European Journal of Clinical Pharmacology.

Is Chronic Dialysis the Right Hard Renal End Point To Evaluate Renoprotective Drug Effects?

P. Mol, D. de Zeeuw, H. Heerspink, 2017, Clinical journal of the American Society of Nephrology : CJASN.

Individual long-term albuminuria exposure during angiotensin receptor blocker therapy is the optimal predictor for renal outcome.

D. de Zeeuw, D. Packham, F. Holtkamp, 2016, Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association.

The renal protective effect of angiotensin receptor blockers depends on intra-individual response variation in multiple risk markers.

H. Parving, D. de Zeeuw, P. Rossing, 2015, British journal of clinical pharmacology.

Monitoring Kidney Function and Albuminuria in Patients With Diabetes

M. Ravid, D. de Zeeuw, H. L. Lambers Heerspink, 2011, Diabetes Care.

Renal risk and renoprotection among ethnic groups with type 2 diabetic nephropathy: a post hoc analysis of RENAAL.

B. Brenner, J. Chan, G. Remuzzi, 2006, Kidney international.

Growth-Differentiation Factor 15 Predicts Worsening of Albuminuria in Patients With Type 2 Diabetes

R. Henning, D. de Zeeuw, S. Bakker, 2012, Diabetes Care.

Short-term antiproteinuric response to antihypertensive treatment predicts long-term GFR decline in patients with non-diabetic renal disease.

D. de Zeeuw, P. D. de Jong, D. Dezeeuw, 1994, Kidney international. Supplement.

Recombinant Semliki Forest virus as a vector system for fast and selective in vivo gene delivery into balloon-injured rat aorta

M. J. Kraak, R. Henning, D. de Zeeuw, 2002, Gene Therapy.

Selection on albuminuria enhances the efficacy of screening for cardiovascular risk factors.

D. de Zeeuw, S. Bakker, R. Gansevoort, 2010, Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association.

N‐terminal pro‐brain natriuretic peptide (NT‐proBNP) predicts the cardio‐renal response to aliskiren in patients with type 2 diabetes at high renal and cardiovascular risk

J. McMurray, B. Brenner, H. Parving, 2018, Diabetes, obesity & metabolism.

Pooled Analysis of Multiple Crossover Trials To Optimize Individual Therapy Response to Renin-Angiotensin-Aldosterone System Intervention.

G. Laverman, D. de Zeeuw, H. Heerspink, 2017, Clinical journal of the American Society of Nephrology : CJASN.

Dual renin-angiotensin system blockade at optimal doses for proteinuria.

R. Henning, G. Navis, G. Laverman, 2002, Kidney international.

Is the antiproteinuric effect of dipyridamole hemodynamically mediated?

D. de Zeeuw, P. D. de Jong, J. van der Meer, 1988, Nephron.

Continuum of renoprotection with losartan at all stages of type 2 diabetic nephropathy: a post hoc analysis of the RENAAL trial results.

B. Dimitrov, B. Brenner, G. Remuzzi, 2004, Journal of the American Society of Nephrology : JASN.

Importance of baseline distribution of proteinuria in renal outcomes trials: lessons from the reduction of endpoints in NIDDM with the angiotensin II antagonist losartan (RENAAL) study.

B. Brenner, D. de Zeeuw, S. Snapinn, 2005, Journal of the American Society of Nephrology : JASN.

Comparison of different measures of urinary protein excretion for prediction of renal events.

B. Brenner, H. Parving, D. de Zeeuw, 2010, Journal of the American Society of Nephrology : JASN.

Early Response in Albuminuria and Long-Term Kidney Protection during Treatment with an Endothelin Receptor Antagonist: A Prespecified Analysis from the SONAR Trial

J. McMurray, H. Parving, V. Perkovic, 2021, Journal of the American Society of Nephrology : JASN.

Falsely low urinary albumin concentrations after prolonged frozen storage of urine samples.

Stephan J L Bakker, Hans L Hillege, D. de Zeeuw, 2005, Clinical chemistry.

The paradox created by commenting on large clinical trial results

D. de Zeeuw, C. Meyer, 2015, Diabetes, obesity & metabolism.

Perspectives on a Way Forward to Implementation of Precision Medicine in Patients With Diabetic Kidney Disease; Results of a Stakeholder Consensus-Building Meeting

M. Kretzler, P. Mol, D. de Zeeuw, 2021, Frontiers in Pharmacology.

The Effect of Atrasentan on Kidney and Heart Failure Outcomes by Baseline Albuminuria and Kidney Function

J. McMurray, H. Parving, G. Bakris, 2021, Clinical journal of the American Society of Nephrology : CJASN.

Prolonged frozen storage of urine reduces the value of albuminuria for mortality prediction.

Stephan J L Bakker, D. de Zeeuw, S. Bakker, 2007, Clinical chemistry.

Do severe systemic sequelae of proteinuria modulate the antiproteinuric response to chronic ACE inhibition?

R. Henning, G. Navis, D. de Zeeuw, 2002, Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association.

Impaired coronary endothelial function in a rat model of spontaneous albuminuria.

Y. Pinto, D. de Zeeuw, H. Buikema, 2002, Kidney international.

Approaches and methods in gene therapy for kidney disease.

R. Henning, D. de Zeeuw, L. Deelman, 2004, Journal of pharmacological and toxicological methods.

Drug-targeting to the kidney: renal delivery and degradation of a naproxen-lysozyme conjugate in vivo.

D. de Zeeuw, D. Meijer, P. D. de Jong, 1997, Kidney international.

Albuminuria, estimated GFR, traditional risk factors, and incident cardiovascular disease: the PREVEND (Prevention of Renal and Vascular Endstage Disease) study.

D. de Zeeuw, H. Hillege, S. Bakker, 2012, American journal of kidney diseases : the official journal of the National Kidney Foundation.

The effect of metformin on blood pressure, plasma cholesterol and triglycerides in type 2 diabetes mellitus: a systematic review.

D. de Zeeuw, R. Gansevoort, C. Stehouwer, 2002, Journal of internal medicine.

A comparison of analytic procedures for measurement of fractional dextran clearances.

D. de Zeeuw, P. D. de Jong, M. Hemmelder, 1998, The Journal of laboratory and clinical medicine.

Renal hemodynamic effects of candesartan in normal and impaired renal function in humans.

D. de Zeeuw, P. D. de Jong, H. Buter, 1997, Kidney international. Supplement.

Progression risk, urinary protein excretion, and treatment effects of angiotensin-converting enzyme inhibitors in nondiabetic kidney disease.

D. Kent, H. Tighiouart, A. Levey, 2007, Journal of the American Society of Nephrology : JASN.

Lisinopril in hypertensive patients with renal function impairment.

D. de Zeeuw, P. D. de Jong, J. Heeg, 1990, Nephron.

Claims in advertisements for antihypertensive drugs in a Dutch medical journal

J. Greving, F. Haaijer-Ruskamp, D. de Zeeuw, 2007, Journal of hypertension.

Cost-effectiveness of early irbesartan treatment versus control (standard antihypertensive medications excluding ACE inhibitors, other angiotensin-2 receptor antagonists, and dihydropyridine calcium channel blockers) or late irbesartan treatment in patients with type 2 diabetes, hypertension, and re

P. Lapuerta, H. Parving, R. Rodby, 2004, Diabetes care.

The sodium‐glucose cotransporter‐2 inhibitor canagliflozin does not increase risk of non‐genital skin and soft tissue infections in people with type 2 diabetes mellitus: A pooled post hoc analysis from the CANVAS Program and CREDENCE randomized double‐blind trials

A. Levin, K. Mahaffey, M. Jardine, 2023, Diabetes, obesity & metabolism.

Renal endothelial function and blood flow predict the individual susceptibility to adriamycin-induced renal damage.

R. Henning, D. de Zeeuw, H. Buikema, 2008, Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association.

Renal targeting of a non-steroidal anti-inflammatory drug: effects on renal prostaglandin synthesis in the rat.

D. de Zeeuw, D. Meijer, P. D. de Jong, 1998, Clinical science.

Involvement of renal ACE activity in proteinuria-associated renal damage in untreated and treated adriamycin nephrotic rats

R. Henning, G. Navis, G. Laverman, 2003, Journal of the renin-angiotensin-aldosterone system : JRAAS.

A Longitudinal Study Examining Adherence to Guidelines in Diabetes Care According to Different Definitions of Adequacy and Timeliness

Flora M. Haaijer-Ruskamp, Petra Denig, F. Haaijer-Ruskamp, 2011, PloS one.

Effects of paricalcitol on calcium and phosphate metabolism and markers of bone health in patients with diabetic nephropathy: results of the VITAL study

D. de Zeeuw, E. Ritz, D. Coyne, 2013, Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association.

A Prospective Cohort Study in Patients with Type 2 Diabetes Mellitus for Validation of Biomarkers (PROVALID) – Study Design and Baseline Characteristics

G. Heinze, A. Więcek, D. de Zeeuw, 2018, Kidney and Blood Pressure Research.

Effects of enalaprilic acid on sodium excretion and renal hemodynamics in essential hypertension.

A. Donker, D. de Zeeuw, P. D. de Jong, 1985, Journal of clinical hypertension.

Proteinuria and cholesterol reduction are independently associated with less renal function decline in statin-treated patients; a post hoc analysis of the PLANET trials

H. Parving, D. de Zeeuw, H. Heerspink, 2018, Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association.

Validity of biomarkers predicting onset or progression of nephropathy in patients with Type 2 diabetes: a systematic review

B. Mayer, D. de Zeeuw, S. Bakker, 2012, Diabetic medicine : a journal of the British Diabetic Association.

Antiproteinuric drugs in patients with idiopathic membranous glomerulopathy.

D. de Zeeuw, R. Gansevoort, P. D. de Jong, 1992, Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association.

Safety, tolerability, pharmacodynamics and pharmacokinetics of the soluble guanylyl cyclase activator BI 685509 in patients with diabetic kidney disease: A randomized trial

M. Nangaku, D. de Zeeuw, F. Schulze, 2023, Diabetes, obesity & metabolism.

Association Between Performance Measures and Glycemic Control Among Patients With Diabetes in a Community-wide Primary Care Cohort

F. Haaijer-Ruskamp, D. de Zeeuw, P. Denig, 2013, Medical care.

Transport mechanisms for cationic drugs and proteins in kidney, liver and intestine: implication for drug interactions and cell-specific drug delivery.

D. de Zeeuw, P. Meier, D. Meijer, 1999, Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association.

Is albuminuria screening and treatment optimal in patients with type 2 diabetes in primary care? Observational data of the GIANTT cohort.

D. de Zeeuw, M. Hellemons, H. L. Lambers Heerspink, 2013, Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association.

Renoprotective therapy: is it blood pressure or albuminuria that matters?

D. de Zeeuw, P. D. de Jong, 2005, Lancet.

[Quality of the treatment of type 2 diabetes: results from the GIANTT project 2004-2007].

B. Wolffenbuttel, F. Haaijer-Ruskamp, D. de Zeeuw, 2010, Nederlandsch tijdschrift voor geneeskunde.

The effects of lowering LDL cholesterol with simvastatin plus ezetimibe in patients with chronic kidney disease (Study of Heart and Renal Protection): a randomised placebo-controlled trial

M. Landray, R. Collins, B. Kasiske, 2011, The Lancet.

Urine collection in the freely moving rat: reliability for measurement of short-term renal effects.

D. de Zeeuw, D. Meijer, P. D. de Jong, 1997, Journal of pharmacological and toxicological methods.

Effects of canagliflozin on amputation risk in type 2 diabetes: the CANVAS Program

K. Mahaffey, R. Hennekam, V. Perkovic, 2019, Diabetologia.

New renal guidelines; is more better?

D. de Zeeuw, P. Denig, 2014, Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association.

Regional Variation in Hemoglobin Distribution Among Individuals With CKD: the ISN International Network of CKD Cohorts

F. Kronenberg, P. Oefner, O. Djurdjev, 2023, Kidney international reports.

Does comorbidity explain trends in prescribing of newer antihypertensive agents?

J. Greving, F. Haaijer-Ruskamp, D. de Zeeuw, 2004, Journal of hypertension.

Angiotensin-converting enzyme gene I/D polymorphism and renal disease

G. Navis, D. de Zeeuw, P. D. de Jong, 1999, Journal of Molecular Medicine.

Patient Outcomes: a Systematic Literature Review Review: Relation between Quality-of-care Indicators for Diabetes and Relation between Quality-of-care Indicators for Diabetes and Patient Outcomes: a Systematic Literature Review

F. Haaijer-Ruskamp, D. de Zeeuw, H. Bilo, 2022 .

Noninvasive measurement of intrarenal blood flow distribution: kinetic model of renal 123I-hippuran handling.

D. de Zeeuw, P. D. de Jong, W. Janssen, 1995, American Journal of Physiology.

[Effect of losartan on renal and cardiovascular complications of patients with type 2 diabetes and nephropathy].

B. Brenner, H. Parving, G. Remuzzi, 2001, Ugeskrift for laeger.

The blood pressure lowering potential of sulodexide--a systematic review and meta-analysis.

D. de Zeeuw, H. L. Lambers Heerspink, B. H. van den Born, 2015, British journal of clinical pharmacology.

Canagliflozin and Renal Outcomes in Type 2 Diabetes and Nephropathy.

B. Zinman, C. Cannon, B. Brenner, 2019, The New England journal of medicine.

Enhanced responses of blood pressure, renal function, and aldosterone to angiotensin I in the DD genotype are blunted by low sodium intake.

R. Henning, G. Navis, D. de Zeeuw, 2002, Journal of the American Society of Nephrology : JASN.

Cardiorenal protective effects of canagliflozin in CREDENCE according to glucose lowering

B. Zinman, A. Levin, K. Mahaffey, 2023, BMJ Open Diabetes Research & Care.

Cost-effectiveness of lipid lowering with statins and ezetimibe in chronic kidney disease

M. Landray, R. Collins, B. Kasiske, 2019, Kidney international.

Plasma 1,25-Dihydroxyvitamin D and the Risk of Developing Hypertension: The Prevention of Renal and Vascular End-Stage Disease Study.

M. M. Joosten, M. Visser, D. de Zeeuw, 2015, Hypertension.

Erythropoietic response and outcomes in kidney disease and type 2 diabetes.

H. Uno, S. Solomon, M. Pfeffer, 2010, The New England journal of medicine.

The effects of lowering LDL cholesterol with simvastatin plus ezetimibe in patients with chronic kidney disease (Study of Heart and Renal Protection): a randomised placebo-controlled trial

M. Landray, R. Collins, B. Kasiske, 2011, The Lancet.

A trial of darbepoetin alfa in type 2 diabetes and chronic kidney disease.

S. Solomon, M. Pfeffer, J. McMurray, 2009, The New England journal of medicine.

Journal of Renin-angiotensin-aldosterone System Journal of Renin-angiotensin-aldosterone System Optimising Renoprotective Therapy? Between-patient Differences in the Renal Response to Renin-angiotensin System Intervention: Clue to Journal of Renin-angiotensin-aldosterone System Additional Services a

G. Navis, G. Laverman, D. de Zeeuw, 2022 .

Effects of lowering LDL cholesterol on progression of kidney disease.

M. Landray, A. Levin, J. Craig, 2014, Journal of the American Society of Nephrology : JASN.

Prognostic clinical and molecular biomarkers of renal disease in type 2 diabetes.

B. Mayer, H. Mischak, J. Jankowski, 2015, Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association.

Sulodexide fails to demonstrate renoprotection in overt type 2 diabetic nephropathy.

E. Lewis, T. Berl, J. Chan, 2012, Journal of the American Society of Nephrology : JASN.

Post-hoc analysis of the SONAR trial indicates that the endothelin receptor antagonist atrasentan is associated with less pain in patients with type 2 diabetes and chronic kidney disease.

D. de Zeeuw, R. Gansevoort, D. Kohan, 2023, Kidney international.

An acute fall in estimated glomerular filtration rate during treatment with losartan predicts a slower decrease in long-term renal function.

Merlin C. Thomas, B. Brenner, H. Parving, 2011, Kidney international.

Review: Relation Between Quality-of-Care Indicators for Diabetes and Patient Outcomes: A Systematic Literature Review

Petra Denig, F. Haaijer-Ruskamp, D. de Zeeuw, 2011, Medical care research and review : MCRR.

Albuminuria, estimated GFR, traditional risk factors, and incident cardiovascular disease: the PREVEND (Prevention of Renal and Vascular Endstage Disease) study.

D. de Zeeuw, H. Hillege, S. Bakker, 2012, American journal of kidney diseases : the official journal of the National Kidney Foundation.

Myocardial infarction does not further impair renal damage in 5/6 nephrectomized rats.

R. Henning, D. de Zeeuw, R. P. van Dokkum, 2008, Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association.

Extended prognostic value of urinary albumin excretion for cardiovascular events.

D. de Zeeuw, S. Bakker, R. Gansevoort, 2008, Journal of the American Society of Nephrology : JASN.

How to measure the prevalence of microalbuminuria in relation to age and gender?

D. de Zeeuw, H. Hillege, P. D. de Jong, 2002, American journal of kidney diseases : the official journal of the National Kidney Foundation.

Sulodexide for kidney protection in type 2 diabetes patients with microalbuminuria: a randomized controlled trial.

E. Lewis, T. Berl, R. Atkins, 2011, American journal of kidney diseases : the official journal of the National Kidney Foundation.

B. Brenner, H. Parving, D. Grobbee, 2011, Hypertension.

Approaches and methods in gene therapy for kidney disease.

R. Henning, D. de Zeeuw, L. Deelman, 2004, Journal of pharmacological and toxicological methods.

The economic benefits of preventing end-stage renal disease in patients with type 2 diabetes mellitus.

M. Postma, D. de Zeeuw, 2009, Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association.

Efficacy and Safety of Canagliflozin in Patients with Type 2 Diabetes and Stage 3 Nephropathy

G. Bakris, V. Perkovic, D. de Zeeuw, 2014, American Journal of Nephrology.

Comparison of different measures of urinary protein excretion for prediction of renal events.

B. Brenner, H. Parving, D. de Zeeuw, 2010, Journal of the American Society of Nephrology : JASN.

Prediction of the effect of atrasentan on renal and heart failure outcomes based on short-term changes in multiple risk markers

H. Parving, G. Remuzzi, V. Perkovic, 2016, European journal of preventive cardiology.

High-sensitivity troponin T predicts worsening of albuminuria in hypertension; results of a nested case–control study with confirmation in diabetes

D. de Zeeuw, S. Bakker, R. Gansevoort, 2013, Journal of hypertension.